# EDGAR Filing Document

**Accession Number:** 0001822479
**File Stem:** 0001822479-26-000031
**Filing Date:** 2026-5
**Character Count:** 168481
**Document Hash:** 8231b6b7ca3dce9a98c1e3b276ff7e8b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001822479-26-000031.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001822479-26-000031

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 76

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sotera Health Co
- **CENTRAL INDEX KEY:** 0001822479
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 473531161
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39729
- **FILM NUMBER:** 26943550

**BUSINESS ADDRESS:**
- **STREET 1:** 9100 SOUTH HILLS BLVD, SUITE 300
- **CITY:** BROADVIEW HEIGHTS
- **STATE:** OH
- **ZIP:** 44147
- **BUSINESS PHONE:** 440-262-1410

**MAIL ADDRESS:**
- **STREET 1:** 9100 SOUTH HILLS BLVD, SUITE 300
- **CITY:** BROADVIEW HEIGHTS
- **STATE:** OH
- **ZIP:** 44147

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sotera Health Topco, Inc.
- **DATE OF NAME CHANGE:** 20200824

?xml version='1.0' encoding='ASCII'? shc-20260331

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026**

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to**

**Commission File Number 001-39729**

![soterahealth_v_clr_rgb_RegisteredMark.jpg](shc-20260331_g1.jpg)

**SOTERA HEALTH COMPANY**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **47-3531161** | **47-3531161** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | (I.R.S. Employer Identification No.) |
| **9100 South Hills Blvd, Suite 300** |  |  |
| **Broadview Heights, Ohio** | **44147** | **44147** |
| (Address of principal executive offices) | (Zip Code) | (Zip Code) |
| Registrant's telephone number, including area code | **(440)** | **262-1410** |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $0.01 par value per share** | **SHC** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of April 28, 2026, there were 285,166,994 shares of the registrant's common stock, $0.01 par value per share, outstanding.

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

**SOTERA HEALTH COMPANY**

**- **TABLE OF CONTENTS** -**

---

| | |
|:---|:---|
| **<u>[Part I—FINANCIAL INFORMATION](#i92a3125af8534be29ee40d5a2264a8b3_13)</u>** | <u>[5](#i92a3125af8534be29ee40d5a2264a8b3_13)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1. Financial Statements](#i92a3125af8534be29ee40d5a2264a8b3_16)</u> | <u>[5](#i92a3125af8534be29ee40d5a2264a8b3_16)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#i92a3125af8534be29ee40d5a2264a8b3_82)</u> | <u>[25](#i92a3125af8534be29ee40d5a2264a8b3_82)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#i92a3125af8534be29ee40d5a2264a8b3_106)</u> | <u>[33](#i92a3125af8534be29ee40d5a2264a8b3_106)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 4. Controls and Procedures](#i92a3125af8534be29ee40d5a2264a8b3_109)</u> | <u>[33](#i92a3125af8534be29ee40d5a2264a8b3_109)</u> |
| **<u>[Part II—OTHER INFORMATION](#i92a3125af8534be29ee40d5a2264a8b3_112)</u>** | <u>[34](#i92a3125af8534be29ee40d5a2264a8b3_112)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1. Legal Proceedings.](#i92a3125af8534be29ee40d5a2264a8b3_115)</u> | <u>[34](#i92a3125af8534be29ee40d5a2264a8b3_115)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 1A. Risk Factors](#i92a3125af8534be29ee40d5a2264a8b3_118)[.](#i92a3125af8534be29ee40d5a2264a8b3_118)</u> | <u>[34](#i92a3125af8534be29ee40d5a2264a8b3_118)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 5. Other Information.](#i92a3125af8534be29ee40d5a2264a8b3_121)</u> | <u>[34](#i92a3125af8534be29ee40d5a2264a8b3_118)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Item 6. Exhibits](#i92a3125af8534be29ee40d5a2264a8b3_124)[.](#i92a3125af8534be29ee40d5a2264a8b3_124)</u> | <u>[35](#i92a3125af8534be29ee40d5a2264a8b3_124)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;**<u>[SIGNATURES](#i92a3125af8534be29ee40d5a2264a8b3_127)</u>** | <u>[36](#i92a3125af8534be29ee40d5a2264a8b3_127)</u> |

---

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are often characterized by the use of words such as "believes," "estimates," "expects," "projects," "may," "intends," "plans" or "anticipates," or by discussions of strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance, achievements, or industry results, to differ materially from historical results or any future results, performance or achievements expressed, suggested or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a disruption in the availability or supply of, or increases in the price of, ethylene oxide ("EO"), Cobalt-60 ("Co-60") or our other direct materials, services and supplies, including as a result of geopolitical instability and/or sanctions against Russia by the United States, Canada, the United Kingdom and/or the European Union, or sanctions by Russia against those countries;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fluctuations in foreign currency exchange rates;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• evolving changes in environmental, health and safety regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• health and safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials such as EO and Co-60;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact and outcome of current and future legal proceedings and liability claims, including litigation related to the use, emissions and releases of EO from our current and former EO sterilization facilities, and the possibility that additional claims will be made in the future;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• allegations of our failure to properly perform services and potential product liability claims, recalls, penalties and reputational harm;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• compliance with the extensive regulatory requirements to which we are subject, the related costs, and any failures to receive or maintain, or delays in receiving, required clearances or approvals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adverse changes in industry trends;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• competition we face;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• market conditions and changes, including inflationary trends and the impact of tariffs, that impact our long-term supply contracts with variable price clauses and increase our cost of revenues;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• business continuity hazards, including supply chain disruptions, federal government shutdowns, and other risks associated with our operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the risks of doing business internationally, including global and regional economic and political instability and

compliance with various applicable laws and potentially inconsistent laws and regulations in multiple jurisdictions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner and renew leases for our leased facilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to attract and retain qualified employees;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• severe health events or environmental events;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• cybersecurity incidents, unauthorized data disclosures, and our dependence on information technology ("IT") systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the risks associated with the introduction of artificial intelligence ("AI") technology;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• an inability to pursue strategic transactions, find suitable acquisition targets, or integrate strategic acquisitions into our business successfully;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to maintain effective internal control over financial reporting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on intellectual property rights to maintain our competitive position and the risk of claims from third parties that we have infringed or misappropriated, or are infringing or misappropriating, their intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to comply with rapidly evolving data privacy and security laws and regulations in various jurisdictions and any ineffective compliance efforts with such laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to generate profitability in future periods;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• impairment charges on our goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the effects of unionization efforts and labor regulations in countries in which we operate;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adverse changes to our tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of U.S. tax legislation or other changes in U.S. or non-U.S. taxation of our operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our significant degree of leverage and how this leverage could adversely affect our ability to raise additional capital, limit our ability to react to challenges facing our Company or broader changes in our industry or the economy, limit our flexibility in operating our business through restrictions contained in our debt agreements and/

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

or prevent us from meeting our obligations under our existing and future agreements governing our indebtedness; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the influence that certain investment funds and entities affiliated with Warburg Pincus and GTCR, which we refer to collectively as the "Sponsors," continue to have over us.

These forward-looking statements are based on current plans, estimates and projections, and therefore you should not place undue reliance on them. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them publicly in light of new information or future events, except as required by law. The inclusion of this forward-looking information should not be regarded as a representation by us or any other person that the future plans, estimates or expectations contemplated by us will be achieved.

You should carefully consider the above factors, as well as the factors discussed elsewhere in this Quarterly Report on Form 10-Q, including under Part II, Item 1A, "Risk Factors," as well as Part I, Item 1A, "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 10-K"). If any of these trends, risks or uncertainties actually occur or continue, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline and you could lose all or part of your investment. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Unless expressly indicated or the context requires otherwise, the terms "Sotera Health," "Company," "we," "us," and "our" in this Quarterly Report on Form 10-Q refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis.

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

**Part I—FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**Sotera Health Company** 

**Consolidated Balance Sheets** 

***(in thousands, except per share amounts)***

---

| | | |
|:---|:---|:---|
| | **As of** | **As of** |
| | **March 31, 2026** | **December 31, 2025** |
| **Assets** | ***(Unaudited)*** | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**314147** | $344621 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted cash short-term | **1798** | 1835 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance for uncollectible accounts of $2,562 and $2,968, respectively | **137256** | 139329 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | **57494** | 54375 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | **68969** | 65250 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes receivable | **6307** | 8000 |
| Total current assets | **585971** | 613410 |
| Property, plant, and equipment, net | **1143452** | 1130564 |
| Operating lease assets | **32896** | 33393 |
| Deferred income taxes | **3769** | 3853 |
| Post-retirement assets | **54953** | 53817 |
| Other assets | **37866** | 36694 |
| Other intangible assets, net | **279357** | 288227 |
| Goodwill | **1097634** | 1103232 |
| Total assets | $**3235898** | $3263190 |
| **Liabilities and equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $**76688** | $77963 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | **85629** | 124736 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | **13741** | 17999 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt | **13983** | 13973 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of finance lease obligations | **3577** | 3465 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease obligations | **5788** | 5755 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | **8398** | 5693 |
| Total current liabilities | **207804** | 249584 |
| Long-term debt | **2124327** | 2126724 |
| Finance lease obligations, less current portion | **93201** | 93835 |
| Operating lease obligations, less current portion | **29381** | 29901 |
| Noncurrent asset retirement obligations | **53852** | 53496 |
| Deferred lease income | **16651** | 17057 |
| Post-retirement obligations | **7983** | 8123 |
| Noncurrent liabilities | **5152** | 7360 |
| Deferred income taxes | **75042** | 71075 |
| Total liabilities | **2613393** | 2657155 |
| See Commitments and contingencies note |  |  |
| Equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, with $0.01 par value, 1,200,000 shares authorized; 286,037 shares issued at March 31, 2026 and December 31, 2025 | **2860** | 2860 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, with $0.01 par value, 120,000 shares authorized; no shares issued at March 31, 2026 and <br>December 31, 2025 | **—** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, at cost (881 and 1,666 shares at March 31, 2026 and December 31, 2025, respectively) | **(12100)** | (17013) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | **1263189** | 1262119 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retained deficit | **(505504)** | (532093) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | **(125940)** | (109838) |
| Total equity | **622505** | 606035 |
| Total liabilities and equity | $**3235898** | $3263190 |

---

*See notes to consolidated financial statements.*

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

**Sotera Health Company** 

**Consolidated Statements of Operations and Comprehensive Income** 

***(in thousands, except per share amounts)***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
|  | ***(Unaudited)*** | ***(Unaudited)*** |
| **Revenues:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Service | $**241608** | $223940 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product | **38437** | 30583 |
| Total net revenues | **280045** | 254523 |
| **Cost of revenues:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Service | **118828** | 107629 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product | **14148** | 11462 |
| **Total cost of revenues** | **132976** | 119091 |
| **Gross profit** | **147069** | 135432 |
| Selling, general and administrative expenses | **68211** | 63061 |
| Amortization of intangible assets | **3031** | 15327 |
| Illinois EO litigation settlement | **—** | 30943 |
| Interest expense, net | **34745** | 40876 |
| Foreign exchange (gain) loss | **(571)** | 289 |
| Other income, net | **(960)** | (241) |
| **Income (Loss) before income taxes** | **42613** | (14823) |
| Provision (Benefit) for income taxes | **16024** | (1563) |
| **Net income (loss)** | **26589** | (13260) |
| **Other comprehensive income (loss) net of tax:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pension and post-retirement benefits (net of taxes of $(36) and $3, respectively) | **(104)** | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest rate derivatives (net of taxes of $560 and $(266), respectively) | **1633** | (772) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign currency translation | **(17631)** | 19560 |
| **Comprehensive income** | $**10487** | $5538 |
| **Earnings (Loss) per share:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $**0.09** | $(0.05) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | **0.09** | (0.05) |
| **Weighted average number of shares outstanding:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | **284887** | 283558 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | **287622** | 283558 |

---

*See notes to consolidated financial statements.* 

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

**Sotera Health Company** 

**Consolidated Statements of Cash Flows** 

***(in thousands)***

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
|  | ***(Unaudited)*** | ***(Unaudited)*** |
| **Operating activities:** |  |  |
| Net income (loss) | $**26589** | $(13260) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | **25212** | 22130 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | **5602** | 18674 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | **4167** | (16075) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | **14393** | 7242 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of asset retirement obligations | **673** | 574 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized foreign exchange (gain) loss | **(2102)** | 5359 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized loss on derivatives not designated as hedging instruments | **1194** | 1604 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs | **1467** | 1270 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | **(1656)** | (1468) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | **891** | 13630 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | **(4088)** | (11839) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | **(2997)** | (3693) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | **2815** | 11671 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | **(10862)** | (10169) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Illinois EO litigation settlements | **(34000)** | 30943 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable / receivable, net | **4049** | (556) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | **(200)** | 71 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term assets | **(1712)** | (587) |
| Net cash provided by operating activities | **29435** | 55521 |
| **Investing activities:** |  |  |
| Purchases of property, plant and equipment | **(46166)** | (19918) |
| Other investing activities | **1038** | 37 |
| Net cash used in investing activities | **(45128)** | (19881) |
| **Financing activities:** |  |  |
| Payment on long-term borrowings | **(3558)** | (3773) |
| Payments of debt issuance costs | **—** | (10) |
| Shares withheld for employee taxes on equity awards | **(8802)** | (3600) |
| Other financing activities | **(419)** | (704) |
| Net cash used in financing activities | **(12779)** | (8087) |
| Effect of exchange rate changes on cash and cash equivalents | **(2039)** | (337) |
| Net (decrease) increase in cash and cash equivalents, including restricted cash | **(30511)** | 27216 |
| Cash and cash equivalents, including restricted cash, at beginning of period | **346456** | 278865 |
| Cash and cash equivalents, including restricted cash, at end of period | $**315945** | $306081 |
| **Supplemental disclosures of cash flow information:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the period for interest | $**36546** | $47416 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the period for income taxes, net of tax refunds received | **9200** | 12215 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment included in accounts payable | **20689** | 13042 |

---

*See notes to consolidated financial statements.*

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

**Sotera Health Company** 

**Consolidated Statements of Equity** 

***(in thousands)***

***(Unaudited)***

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Shares** | **Amount** | **Amount** | **Additional**<br>**Paid-In**<br>**Capital** | **Retained Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**(Loss) Income** | **Total** <br>**Equity** |
| | **Common**<br>**Stock** | **Common**<br>**Stock** | **Treasury**<br>**Stock** | **Additional**<br>**Paid-In**<br>**Capital** | **Retained Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**(Loss) Income** | **Total** <br>**Equity** |
| **Balance at December 31, 2024** | **283466** | $**2860** | $**(23434)** | $**1243778** | $**(610042)** | $**(208251)** | $**404911** |
| Share-based compensation plans | 389 |  | 2579 | 1063 |  |  | **3642** |
| Comprehensive income (loss): |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Pension and post-retirement plan adjustments, net of tax |  |  |  |  |  | 10 | **10** |
| &nbsp;&nbsp;&nbsp;Foreign currency translation |  |  |  |  |  | 19560 | **19560** |
| &nbsp;&nbsp;&nbsp;Interest rate derivatives, net of tax |  |  |  |  |  | (772) | **(772)** |
| &nbsp;&nbsp;&nbsp;Net loss |  |  |  |  | (13260) |  | **(13260)** |
| **Balance at March 31, 2025** | **283855** | $**2860** | $**(20855)** | $**1244841** | $**(623302)** | $**(189453)** | $**414091** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Shares** | **Amount** | **Amount** | **Additional**<br>**Paid-In**<br>**Capital** | **Retained Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**(Loss) Income** | **Total** <br>**Equity** |
| | **Common**<br>**Stock** | **Common**<br>**Stock** | **Treasury**<br>**Stock** | **Additional**<br>**Paid-In**<br>**Capital** | **Retained Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**(Loss) Income** | **Total** <br>**Equity** |
| **Balance at December 31, 2025** | **284371** | $**2860** | $**(17013)** | $**1262119** | $**(532093)** | $**(109838)** | $**606035** |
| Share-based compensation plans | 785 |  | 4913 | 1070 |  |  | **5983** |
| Comprehensive income (loss): |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Pension and post-retirement plan adjustments, net of tax |  |  |  |  |  | (104) | **(104)** |
| &nbsp;&nbsp;&nbsp;Foreign currency translation |  |  |  |  |  | (17631) | **(17631)** |
| &nbsp;&nbsp;&nbsp;Interest rate derivatives, net of tax |  |  |  |  |  | 1633 | **1633** |
| &nbsp;&nbsp;&nbsp;Net income |  |  |  |  | 26589 |  | **26589** |
| **Balance at March 31, 2026** | **285156** | $**2860** | $**(12100)** | $**1263189** | $**(505504)** | $**(125940)** | $**622505** |

---

*See notes to consolidated financial statements.*

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

**1. Basis of Presentation**

*Principles of Consolidation* – Sotera Health Company (also referred to herein as the "Company," "we," "our," "us" or "its"), is a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry with operations primarily in the Americas, Europe and Asia.

We operate and report in three segments: Sterigenics, Nordion and Nelson Labs. We describe our reportable segments in Note 15, "Segment Information". All intercompany balances and transactions have been eliminated in consolidation.

*Use of Estimates* – In preparing our consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles ("GAAP"), we make estimates and assumptions that affect the amounts reported and the accompanying notes. We regularly evaluate the estimates and assumptions used and revise them as new information becomes available. Actual results may vary from those estimates.

*Interim Financial Statements* – The accompanying consolidated financial statements include the assets, liabilities, operating results, and cash flows of the Company and its wholly owned subsidiaries. These financial statements are prepared in accordance with U.S. GAAP for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. These unaudited interim financial statements should be read in conjunction with the Company's annual consolidated financial statements and accompanying notes in our 2025 10-K.

**2. Recent Accounting Standards**

***ASUs Issued But Not Yet Adopted***

In November 2024, the FASB issued ASU 2024-03-Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The amendments in this ASU require entities to disaggregate certain expense captions into specified categories in disclosures within the footnotes to the financial statements. In January 2025, the FASB issued ASU 2025-01, which revises the effective date of ASU 2024-03 and clarifies that entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. The Company expects that this ASU will increase disclosures in the annual and interim periods when adopted.

**3. Revenue Recognition**

The following table shows disaggregated net revenues from contracts with external customers by timing of revenue and by segment for the three months ended March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
|  | **Sterigenics** | **Nordion** | **Nelson Labs** | **Consolidated** |
| **Point in time** | $186135 | $41014 | $— | $227149 |
| **Over time** |  | 995 | 51901 | 52896 |
| **Total** | $**186135** | $**42009** | $**51901** | $**280045** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
|  | **Sterigenics** | **Nordion** | **Nelson Labs** | **Consolidated** |
| **Point in time** | $169684 | $32300 | $— | $201984 |
| **Over time** |  | 257 | 52282 | 52539 |
| **Total** | $**169684** | $**32557** | $**52282** | $**254523** |

---

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

When we receive consideration from a customer prior to transferring goods or services under the terms of a sales contract, we record deferred revenue, which represents a contract liability. Deferred revenue totaled $13.7 million and $18.0 million at March 31, 2026 and December 31, 2025, respectively. We recognize deferred revenue after we have transferred control of the goods or services to the customer and all revenue recognition criteria are met.

**4. Inventories**

Inventories consisted of the following:

---

| | | |
|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* |  |  |
|  | **March 31, 2026** | **December 31, 2025** |
| Raw materials and supplies | $**51303** | $45569 |
| Work-in-process | **347** | 2436 |
| Finished goods | **6091** | 6622 |
|  | **57741** | 54627 |
| Reserve for excess and obsolete inventory | **(247)** | (252) |
| **Inventories, net** | $**57494** | $54375 |

---

**5. Prepaid Expenses and Other Current Assets**

Prepaid expenses and other current assets consisted of the following:

---

| | | |
|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* |  |  |
|  | **March 31, 2026** | **December 31, 2025** |
| Prepaid taxes | $**5625** | $5212 |
| Prepaid business insurance | **5279** | 3974 |
| Prepaid rent | **4852** | 4466 |
| Customer contract assets | **29126** | 24410 |
| Current deposits | **218** | 283 |
| Prepaid maintenance contracts | **802** | 490 |
| Value added tax receivable | **3633** | 4527 |
| Prepaid software licensing | **2767** | 2661 |
| Stock supplies | **5344** | 5012 |
| Embedded derivative assets | **1988** | 1162 |
| Other | **9335** | 13053 |
| **Prepaid expenses and other current assets** | $**68969** | $65250 |

---

**6. Goodwill and Other Intangible Assets**

Changes to goodwill during the three months ended March 31, 2026 were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* | **Sterigenics** | **Nordion** | **Nelson Labs** | **Total** |
| Goodwill at December 31, 2025 | $658919 | $267771 | $176542 | $1103232 |
| Changes due to foreign currency exchange rates | (607) | (4264) | (727) | (5598) |
| **Goodwill at March 31, 2026** | $**658312** | $**263507** | $**175815** | $**1097634** |

---

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

Other intangible assets consisted of the following:

---

| | | |
|:---|:---|:---|
| *(thousands of U.S. dollars)* | **Gross Carrying**<br>**Amount** | **Accumulated**<br>**Amortization** |
| **<u>As of March 31, 2026</u>** | **Gross Carrying**<br>**Amount** | **Accumulated**<br>**Amortization** |
| ***Finite-lived intangible assets*** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | $**166479** | $**86550** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proprietary technology | **37132** | **19400** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade names | **2400** | **2120** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Land-use rights | **8979** | **2398** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sealed source and supply agreements | **166033** | **92053** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | **600** | **530** |
| **Total finite-lived intangible assets** | **381623** | **203051** |
| ***Indefinite-lived intangible assets*** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory licenses and other<sup>(a)</sup> | **74844** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade names / trademarks | **25941** |  |
| **Total indefinite-lived intangible assets** | **100785** |  |
| **Total** | $**482408** | $**203051** |

---

---

| | | |
|:---|:---|:---|
| **<u>As of December 31, 2025</u>** | **Gross Carrying**<br>**Amount** | **Accumulated**<br>**Amortization** |
| ***Finite-lived intangible assets*** | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Customer relationships | $167313 | $84083 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proprietary technology | 37775 | 19253 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade names | 2400 | 2000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Land-use rights | 8861 | 2313 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sealed source and supply agreements | 168740 | 91405 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 900 | 790 |
| **Total finite-lived intangible assets** | 385989 | 199844 |
| ***Indefinite-lived intangible assets*** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory licenses and other<sup>(a)</sup> | 76064 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade names / trademarks | 26018 |  |
| **Total indefinite-lived intangible assets** | 102082 |  |
| **Total** | $488071 | $199844 |

---

<sup>(a)</sup>Includes certain transportation certifications, a class 1B nuclear license and other intangible assets related to obtaining such licensure. These assets are considered indefinite-lived as the decision for renewal by the Canadian Nuclear Safety Commission ("CNSC") is highly based on a licensee's previous assessments, reported incidents, and annual compliance and inspection results. New applications for a license can take a significant amount of time and cost; whereas an existing licensee with a historical record of compliance and current operating conditions is generally expected to obtain renewal, as Nordion has demonstrated over its 75 years of history. In September 2025, the CNSC renewed Nordion's Class 1B nuclear license for a 25-year term.

Amounts include the impact of foreign currency translation. Fully amortized amounts are written off.

Amortization expense for finite-lived intangible assets was $5.6 million and $18.7 million for the three months ended March 31, 2026 and 2025, respectively. $3.0 million and $15.3 million was included in "Amortization of intangible assets" in the Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2026 and 2025, respectively, whereas the remainder was included in "Cost of revenues."

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

The estimated aggregate amortization expense for finite-lived intangible assets for each of the next five years and thereafter is as follows:

---

| | |
|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* |  |
| For the remainder of 2026 | $**16451** |
| 2027 | **20868** |
| 2028 | **20320** |
| 2029 | **20210** |
| 2030 | **20210** |
| Thereafter | **80513** |
| **Total** | $**178572** |

---

**7. Accrued Liabilities**

Accrued liabilities consisted of the following:

---

| | | |
|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* |  |  |
|  | **March 31, 2026** | **December 31, 2025** |
| Accrued employee compensation | $**29914** | $43543 |
| Reserve for Illinois EO litigation settlements | **—** | 34000 |
| Accrued interest expense | **19109** | 20543 |
| Embedded derivatives | **3862** | 1872 |
| Professional fees | **19487** | 10483 |
| Accrued utilities | **1905** | 1786 |
| Insurance accrual | **2365** | 2131 |
| Accrued taxes | **3309** | 3287 |
| Other | **5678** | 7091 |
| **Accrued liabilities** | $**85629** | $124736 |

---

**8. Long-Term Debt**

Long-term debt consisted of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* |  |  |  |  |
| **<u>As of March 31, 2026</u>** | **Gross Amount** | **Unamortized Debt Issuance Costs** | **Unamortized Debt Discount** | **Net Amount** |
| Secured Notes due 2031 | $**750000** | $**(2985)** | $**—** | $**747015** |
| Term Loan due 2031 | **1415915** | **(6312)** | **(18308)** | **1391295** |
|  | **2165915** | **(9297)** | **(18308)** | **2138310** |
| Less current portion | **14230** | **(63)** | **(184)** | **13983** |
| **Long-Term Debt** | $**2151685** | $**(9234)** | $**(18124)** | $**2124327** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* |  |  |  |  |
| **As of December 31, 2025** | **Gross Amount** | **Unamortized Debt Issuance Costs** | **Unamortized Debt Discount** | **Net Amount** |
| Secured Notes due 2031 | $750000 | $(3129) | $— | $746871 |
| Term Loan due 2031 | 1419472 | (6618) | (19028) | 1393826 |
|  | 2169472 | (9747) | (19028) | 2140697 |
| Less current portion | 14230 | (66) | (191) | 13973 |
| **Long-Term Debt** | $2155242 | $(9681) | $(18837) | $2126724 |

---

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

**Debt Facilities**

Under the debt agreements summarized below, at March 31, 2026 we and Sotera Health Holdings, LLC ("SHH"), our wholly owned subsidiary, had debt payment obligations under (a) a term loan in the amount of $1,415.9 million, (b) a revolving credit facility, which supported operationally-related letters of credit but was otherwise undrawn, and which provides to us capacity up to $600.0 million for future potential borrowings, and (c) $750.0 million of senior secured notes. Our debt agreements also include additional covenants, conditions and rights to request additional debt, as summarized below.

*Senior Secured Credit Facilities and Indenture*

On December 13, 2019, SHH entered into senior secured first lien credit facilities (the "Senior Secured Credit Facilities"), consisting of both a prepayable senior secured first lien term loan (the "Term Loans") and a senior secured first lien revolving credit facility (the "Revolving Credit Facility") pursuant to a first lien credit agreement (as amended through Amendment No. 6, the "Credit Agreement"). The Senior Secured Credit Facilities also provide SHH the right at any time and under certain conditions to request incremental term loans or incremental revolving credit commitments based on a formula defined in the Senior Secured Credit Facilities.

The weighted average interest rates on borrowings under the Term Loans for the three months ended March 31, 2026 and March 31, 2025 was 6.23% and 7.65%, respectively.

On May 30, 2024, SHH, the Company, certain subsidiaries of the Company (the "Guarantors"), and Wilmington Trust, National Association, as trustee, paying agent, registrar, transfer agent and notes collateral agent, entered into an Indenture (the "Indenture") governing SHH's $750.0 million aggregate principal amount of 7.375% senior secured notes due 2031 (the "Secured Notes") issued in May 2024. The Secured Notes pay interest semiannually in arrears on June 1 and December 1 of each year, which began on December 1, 2024, at a rate of 7.375% per year, and will mature on June 1, 2031.

Outstanding letters of credit are collateralized by encumbrances against the Revolving Credit Facility and the collateral pledged thereunder, or by cash placed on deposit with the issuing bank. As of March 31, 2026, the Company had $8.3 million of letters of credit issued against the Revolving Credit Facility, resulting in total availability under the Revolving Credit Facility of $591.7 million.

**9. Income Taxes**

Income tax expense (benefit) is provided on an interim basis based upon our estimate of the annual effective income tax rate. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and the taxing jurisdictions where the earnings will occur, the impact of state and local taxes, our ability to utilize tax credits and net operating loss carryforwards and available tax planning alternatives. Our effective tax rate was 37.6% and 10.5% for the three months ended March 31, 2026 and March 31, 2025, respectively.

Income tax expense for the three months ended March 31, 2026 differed from the statutory rate primarily due to the foreign rate differential, current year permanent differences, including foreign withholding taxes and other non-deductible items, and U.S. state income taxes (net of federal tax benefit). Income tax expense for the three months ended March 31, 2025 differed from the statutory rate primarily due to current year permanent differences, partially offset by the valuation allowance attributable to the limitation on the deductibility of interest expense and the impact of the foreign rate differential.

**10. Employee Benefits**

The Company sponsors various post-employment benefit plans including, in certain countries outside the U.S., defined benefit and defined contribution pension plans, retirement compensation arrangements, and plans that provide extended health care coverage to retired employees, the majority of which relate to Nordion. The interest cost, expected return on plan assets and amortization of net actuarial gain are recorded in "Other income, net" and the service cost component is included in the same financial statement line item as the applicable employee's wages in the Consolidated Statements of Operations and Comprehensive Income.

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

*Defined benefit pension plan* 

The following defined benefit pension plan disclosure relates to Nordion. Certain immaterial foreign defined benefit pension plans have been excluded from the table below. The components of net periodic pension benefit for the defined benefit plans for the three months ended March 31, 2026 and 2025 were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *<u>(thousands of U.S. dollars)</u>* | **March 31,<br>2026** | **March 31,<br>2025** |
| Service cost | $**118** | $120 |
| Interest cost | **2327** | 2307 |
| Expected return on plan assets | **(4229)** | (3852) |
| **Net periodic benefit** | $**(1784)** | $(1425) |

---

*Other benefit plans* 

Other benefit plans disclosed below relate to Nordion and include a supplemental retirement arrangement, a retirement and termination allowance, and post-retirement benefit plans, which include contributory health and dental care benefits and contributory life insurance coverage. Certain immaterial other foreign benefit plans have been excluded from the table below. All non-pension post-employment benefit plans are unfunded. The components of net periodic pension cost for the other benefit plans for the three months ended March 31, 2026 and 2025 were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *<u>(thousands of U.S. dollars)</u>* | **March 31,<br>2026** | **March 31,<br>2025** |
| Service cost | $**1** | $1 |
| Interest cost | **77** | 76 |
| Amortization of net actuarial gain | **(34)** | (18) |
| **Net periodic benefit cost** | $**44** | $59 |

---

**11. Other Comprehensive Income (Loss)**

Amounts in accumulated other comprehensive income (loss) are presented net of the related tax. Foreign currency translation is not adjusted for income taxes.

Changes in our accumulated other comprehensive income (loss) balances, net of applicable tax, were as follows:

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* | **Defined**<br>**Benefit**<br>**Plans** |  | **Foreign**<br>**Currency**<br>**Translation** | **Interest**<br>**Rate**<br>**Derivatives** |  | **Total** |
| **Beginning balance – January 1, 2026** | $**3551** |  | $**(111551)** | $**(1838)** |  | $**(109838)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before<br>reclassifications | **(70)** |  | **(17631)** | **1665** |  | **(16036)** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from accumulated other<br>comprehensive income (loss) | **(34)** | (a) | **—** | **(32)** | (b) | **(66)** |
| **Net current-period other comprehensive income (loss)** | **(104)** |  | **(17631)** | **1633** |  | **(16102)** |
| **Ending balance – March 31, 2026** | $**3447** |  | $**(129182)** | $**(205)** |  | $**(125940)** |
| **Beginning balance – January 1, 2025** | $1165 |  | $(209666) | $250 |  | $(208251) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income (loss) before<br>reclassifications | 28 |  | 19560 | (520) |  | 19068 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from accumulated other<br>comprehensive income (loss) | (18) | (a) |  | (252) | (b) | (270) |
| **Net current-period other comprehensive income (loss)** | 10 |  | 19560 | (772) |  | 18798 |
| **Ending balance – March 31, 2025** | $1175 |  | $(190106) | $(522) |  | $(189453) |

---

(a)For defined benefit pension plans, amounts reclassified from accumulated other comprehensive income (loss) are recorded to "Other income, net" within the Consolidated Statements of Operations and Comprehensive Income.

(b)For interest rate derivatives, amounts reclassified from accumulated other comprehensive income (loss) are recorded to "Interest expense, net" within the Consolidated Statements of Operations and Comprehensive Income.

**12. Earnings (Loss) Per Share** 

Basic earnings per share represents the amount of income attributable to each common share outstanding. Diluted earnings per share represents the amount of income attributable to each common share outstanding adjusted for the effects of potentially dilutive common shares. Potentially dilutive common shares include stock options and other stock-based awards. In the periods where the effect would be antidilutive, potentially dilutive common shares are excluded from the calculation of diluted earnings per share.

For 2025 and prior years, in periods in which the Company had net income, earnings per share was calculated using the two-class method. This method was required as unvested pre-IPO restricted stock awards had the right to receive non-forfeitable dividends or dividend equivalents if the Company were to declare dividends on its common stock. Pursuant to the two-class method, earnings for each period were allocated on a pro-rata basis to common stockholders and unvested pre-IPO restricted stock awards. Diluted earnings per share was computed using the more dilutive of the (a) two-class method, and (b) treasury stock method, as applicable, to the potentially dilutive instruments.

In periods in which the Company had a net loss, the two-class method was not applicable because the unvested pre-IPO restricted stock awards did not participate in losses.

Beginning in 2026, earnings per share is calculated using the treasury stock method. As all pre-IPO restricted stock awards were fully vested in the third quarter of 2025, the use of the two-class method is no longer required. Diluted earnings per share represents the weighted average number of common shares outstanding plus the dilutive effect of potential common shares calculated using the treasury stock method.

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

Our basic and diluted earnings (loss) per common share are calculated as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *<u>in thousands of U.S. dollars and share amounts (except per share amounts)</u>* | **March 31,<br>2026** | **March 31,<br>2025** |
| **Earnings (Loss):** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $**26589** | $(13260) |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Allocation to participating securities | **—** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) attributable to Sotera Health Company common shareholders | $**26589** | $(13260) |
| **Weighted Average Common Shares:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-average common shares outstanding - basic | **284887** | 283558 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dilutive effect of potential common shares<sup>(a)</sup> | **2735** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-average common shares outstanding - diluted | **287622** | 283558 |
| **Earnings (Loss) per Common Share:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) attributable to Sotera Health Company common shareholders - basic | $**0.09** | $(0.05) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) attributable to Sotera Health Company common shareholders - diluted | **0.09** | (0.05) |

---

(a)As the Company reported a net loss for the three months ended March 31, 2025, the calculation of diluted weighted average common shares outstanding is not applicable because the effect of including the potential common shares would be anti-dilutive.

Diluted earnings (loss) per share does not consider the following potential common shares as the effect would be anti-dilutive:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended** | **Three Months Ended** |
| *<u>in thousands of share amounts</u>* | **March 31,<br>2026** | **March 31,<br>2025** |
| Stock options | **4753** | 5601 |
| RSUs and PSUs | **69** | 234 |
| **Total anti-dilutive securities** | **4822** | 5835 |

---

**13. Commitments and Contingencies**

From time to time, we may be or are subject to various lawsuits and other claims, as well as gain contingencies, in the ordinary course of our business. In addition, from time to time, we receive communications from government or regulatory agencies concerning investigations or allegations of noncompliance with laws or regulations in jurisdictions in which we operate. We assess these regulatory and legal actions to determine if a contingent liability should be recorded. In making these determinations, we may, depending on the nature of the matter, consult with internal and external legal counsel and technical experts.

We establish reserves for specific liabilities in connection with regulatory and legal actions that we determine to be both probable and reasonably estimable. The outcomes of regulatory and legal actions can be difficult to predict and are often resolved over long periods of time, making our probability and estimability determinations highly judgmental. Probability determinations require the analysis of various possible outcomes, assessments of potential damages and the impact of multiple factors beyond our control, including potential actions by others, interpretations of the law, and changes and developments in relevant facts, circumstances, regulations and other laws. If a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability is disclosed, together with an estimate of the range of possible loss if the range is determinable and material. In certain of the matters described below, we are not able to estimate potential liability because of the uncertainties related to the outcome(s) and/or the amount(s) or range(s) of loss. The ultimate resolution of pending regulatory and legal matters in future periods, including the matters described below, may have a material adverse effect on our financial condition, results of operations and/or liquidity. The Company may also incur material defense and settlement costs, diversion of management resources and other adverse effects on our business, financial condition, and/or results of operations.

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

The information regarding those matters set forth below is as of March 31, 2026, except as otherwise indicated.

*<u>Ethylene Oxide Tort Litigation</u>*

Sterigenics U.S., LLC ("Sterigenics") and other medical supply sterilization companies have been subjected to tort lawsuits alleging various injuries caused by low-level environmental exposure to EO used at or emitted or released from sterilization facilities. Those lawsuits, as detailed further below, are individual claims, as opposed to class actions.

*California*

As of April 30, 2026, subsidiaries of the Company and other parties are defendants in lawsuits pending in Los Angeles County Superior Court in which the plaintiffs assert approximately 140 claims for personal injury or wrongful death allegedly resulting from use, emissions and releases of EO from Sterigenics' Vernon facilities (the "Vernon Cases"). The Vernon Cases have been assigned to one judge, with initial trials scheduled for January and April 2027. Eight individual claims have been selected as the "First Plaintiff Group" and are being prioritized for discovery.

*Georgia*

Subsidiaries of the Company and other parties are defendants in lawsuits in Georgia in which plaintiffs allege personal injuries, wrongful death and property devaluation resulting from use, emissions and releases of EO from or at Sterigenics' Atlanta facility.

As of April 30, 2026, approximately 470 personal injury and wrongful death claims filed in the State Court of Cobb County (the "Georgia Trial Court") are assigned to a single judge (the "Georgia Personal Injury Cases"). The Georgia Personal Injury Cases are governed by case management orders pursuant to which general causation issues in a pool of eight cases were to be adjudicated in Phase 1 and specific causation issues in those pool cases were to be adjudicated in Phase 2; the remaining Georgia Personal Injury Cases, including 15 cases that include both personal injury and property claims and one personal injury lawsuit that is pending before a different judge, are stayed.

On November 22, 2024, the Georgia Trial Court issued a Phase 1 ruling on general causation issues granting in part and denying in part defendants' motions to exclude certain Phase 1 expert testimony and defendants' motions for summary judgment on Phase 1 issues (the "First General Causation Ruling"). Plaintiffs and defendants appealed the First General Causation Ruling to the Court of Appeals of Georgia (the "Phase 1 General Causation Appeals"). While the Phase 1 General Causation Appeals were pending, three of the pool cases, selected by plaintiffs' counsel, proceeded to Phase 2 (the "Phase 2 Cases"). On October 17, 2025, the Georgia Trial Court issued its Phase 2 rulings on specific causation issues granting Sterigenics' motions to exclude three of plaintiffs' specific causation expert witnesses and granting Sterigenics' motions for summary judgment in all three Phase 2 Cases (the "Specific Causation Ruling"). On October 28, 2025, the Georgia Trial Court entered an order also adopting its Specific Causation Ruling with respect to our subsidiary Sotera Health LLC. Plaintiffs in the Phase 2 Cases appealed the Specific Causation Ruling to the Court of Appeals of Georgia (the "Phase 2 Specific Causation Appeals").

On October 31, 2025, the Court of Appeals of Georgia ruled on the Phase 1 General Causation Appeals, finding that as Sterigenics contended on appeal, the First General Causation Ruling failed to apply the proper standard for determining the admissibility of expert testimony on general causation, vacating the First General Causation Ruling and remanding the pool cases to the Georgia Trial Court with instructions to apply the proper standard in ruling on general causation issues. The Court of Appeals also instructed the Georgia Trial Court to consider whether plaintiffs can prove general causation through epidemiological evidence and background risks of the diseases at issue. On March 30, 2026, the Georgia Trial Court granted defendants' motions to exclude plaintiffs' general causation experts and entered summary judgment for defendants in the five remanded pool cases (the "Second General Causation Ruling and Judgment"). Plaintiffs in the five remanded pool cases appealed the Second General Causation Ruling and Judgment to the Court of Appeals of Georgia.

Subsidiaries of the Company and other parties are also defendants in a lawsuit filed in May 2020 in which employees of a sterilization customer of Sterigenics allege they were injured while working at the customer's distribution facility by exposure to residual EO allegedly emanating from products of the customer that had been sterilized by Sterigenics. The case is proceeding in the Superior Court of Cobb County on plaintiffs' Fifth Amended Complaint. Pursuant to the customer's contract with Sterigenics, the customer is indemnifying Sterigenics against this lawsuit.

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

As of April 30, 2026, approximately 305 lawsuits have been filed in the Georgia Trial Court against subsidiaries of the Company and other parties in which plaintiffs allege property devaluation resulting from use, emissions and releases of EO from or at Sterigenics' Atlanta facility. These cases have been consolidated for pretrial purposes (the "Consolidated Property Cases"). Proceedings in a pool of nine of the Consolidated Property Cases are governed by case management orders pursuant to which the parties completed discovery and defendants filed motions to exclude certain plaintiffs' expert testimony and motions for summary judgment, which remain pending. The remaining cases are stayed.

*Illinois*

Lawsuits against subsidiaries of the Company and other parties have been filed in the Circuit Court of Cook County, Illinois, by plaintiffs alleging personal injury or wrongful death resulting from use, emissions and releases of EO from Sterigenics' former Willowbrook facility (the "Illinois Cases"). As of April 30, 2026, subsidiaries of the Company and other parties are defendants in approximately 10 Illinois Cases that are in various stages of pleadings, motions practice and fact discovery.

*New Mexico*

The Company and certain subsidiaries are defendants in a lawsuit filed in the Third Judicial District Court, Doña Ana County, New Mexico (the "Trial Court") in which the New Mexico Attorney General ("NMAG") alleges that use, emissions and releases of EO from Sterigenics' facility in Santa Teresa have deteriorated the air quality in surrounding communities and materially contributed to increased health risks for residents of those communities and seeks declaratory and permanent injunctive relief and damages. In April 2024, the Court of Appeals of the State of New Mexico denied the NMAG's petition for leave to file an interlocutory appeal of the Trial Court's August 2023 order granting Sterigenics' motion for summary judgment on strict liability, the Unfair Practices Act claim, and the claims for decreased property values, increased healthcare costs and medical monitoring costs, and remanded the case to the District Court of Doña Ana County for further proceedings on the remaining claims. In January 2026, the Trial Court denied NMAG's May 2025 motion to modify the Trial Court's August 2023 summary judgment order to reinstate the NMAG's claim for recovery of healthcare cost damages. The case is set for trial in July 2026.

\* \* \*

Additional EO lawsuits have been threatened relating to Sterigenics' current and former EO sterilization facilities in the United States and may be filed in the future. These threats of additional EO lawsuits are comparable to threats that have similarly been made against other companies within our industry. Based on our view of the strength of the science and related evidence that emissions of EO from Sterigenics' operations have not caused and could not have caused the harms alleged in such lawsuits, we believe that losses in the remaining or future EO cases through trials and any appeals that may prove necessary are not probable. Although the Company is vigorously defending against the EO tort claims, future settlements of EO tort claims are reasonably possible. The previously disclosed settlements of certain cases related to our facilities in Willowbrook and Atlanta were driven by dynamics unique to the claims that were settled and thus should not give rise to presumptions that the Company will settle additional EO tort claims and/or that any such settlements will be for comparable amounts.

Potential trial and settlement outcomes can vary widely based on a host of factors. EO tort lawsuits will be presided over by different judges, tried by different counsel presenting different evidence and decided by different juries. The substantive and procedural laws of jurisdictions vary and can meaningfully impact the litigation process and outcome of a case. Each plaintiff's claim involves unique facts and evidence, including the circumstances of the plaintiff's alleged exposure, the type and severity of the plaintiff's disease, the plaintiff's medical history and course of treatment, the location of and other factors related to the plaintiff's real property, and other circumstances. The outcomes of trials before juries are rarely certain and a judgment rendered or settlement reached in one case is not necessarily representative of potential outcomes of other seemingly comparable cases. As a result, it is not possible to estimate a reasonably possible loss or range of loss with respect to any future EO tort lawsuit, trial or settlement. We are vigorously defending the EO tort lawsuits.

*<u>Insurance Coverage for Environmental Liabilities</u>*

An environmental liability insurance policy under which we received coverage for certain of the EO tort lawsuits described above has been exhausted. We sought to obtain additional insurance coverage for these tort claims; however, our existing insurance policies exclude coverage for EO tort lawsuits, and we may not be able to secure additional coverage for these matters in the future. On August 27, 2021, Sterigenics filed an insurance coverage lawsuit in the U.S. District Court for the Northern District of Illinois (the "Illinois District Court") relating to two commercial general liability policies issued in the

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

1980s (the "Northern District of Illinois Coverage Lawsuit"). The Illinois District Court issued an order declaring that the defendant insurer owes a duty to Sterigenics and another insured party to defend the Illinois Cases (the "Duty to Defend Order") and entered judgment for Sterigenics for certain defense costs incurred in the Illinois Cases. The defendant insurer appealed to the United States Court of Appeals for the Seventh Circuit. On January 23, 2026, the Illinois Supreme Court issued an opinion on a question of Illinois law certified to it by the Seventh Circuit Court of Appeals, holding that a permit or regulation authorizing emissions plays no role in assessing the application of a pollution exclusion in a standard form commercial general liability policy. On March 13, 2026, the Seventh Circuit Court of Appeals reversed the Duty to Defend Order and remanded the case to the Illinois District Court which then entered judgment in favor of the defendant insurer. In light of the rulings by the Illinois Supreme Court and Seventh Circuit Court of Appeals, Sterigenics has agreed to withdraw claims for EO tort lawsuit coverage under other historical commercial general liability policies. Coverage lawsuits filed in the Delaware Superior Court, the Los Angeles County Superior Court and the Circuit Court of Cook County, Illinois relating to those claims will be dismissed. If other historical insurance coverage for EO tort lawsuits is identified, coverage claims may be pursued, but it is not possible to predict how much coverage, if any, could ultimately be recovered.

*<u>Sotera Health Company Securities Litigation and Related Matters</u>*

In January 2023, a stockholder class action was filed in the U.S. District Court for the Northern District of Ohio (the "Ohio District Court") against the Company and certain past and present directors and senior executives, the Company's private equity stockholders and the underwriters of the Company's IPO in November 2020 and the Company's secondary public offering ("SPO") in March 2021 on behalf of a proposed class of stockholders who acquired shares of the Company between November 20, 2020 and September 19, 2022 (the "Michigan Funds Litigation"). Plaintiffs sought damages for alleged violations of the Securities Act of 1933 and the Exchange Act in certain statements made in connection with the Company's IPO and March 2021 SPO regarding the safety of the Company's use of EO and/or the EO tort lawsuits and other risks of its EO operations. On March 19, 2025, the Ohio District Court granted the Company's motion to dismiss and entered judgment dismissing the Michigan Funds Litigation with prejudice (the "Dismissal Order and Judgment"). Plaintiffs appealed, and on February 24, 2026, the United States Court of Appeals for the Sixth Circuit affirmed the Dismissal Order and Judgment.

In May 2024, a stockholder derivative lawsuit was filed in the Court of Chancery of the State of Delaware (the "Delaware Chancery Court") for the benefit of the Company as the nominal defendant (the "May 2024 Derivative Litigation"). The plaintiffs alleged breaches of fiduciary duties, insider trading, unjust enrichment and other violations by certain past and present directors and senior executives of the Company and the Company's private equity stockholders, and sought damages sustained by the Company and other forms of relief including restitution, rescission and disgorgement. The May 2024 Derivative Litigation was stayed pending a ruling on the merits in the Michigan Funds Litigation. Following the United States Court of Appeals for the Sixth Circuit's affirmance of the District Court's Dismissal Order and Judgment, the plaintiffs filed a notice of voluntary dismissal. On March 31, 2026, the Delaware Chancery Court dismissed the May 2024 Derivative Litigation.

The Company also received demands pursuant to 8 Del. C. §220 for inspections of its books and records ("220 Demands") from shareholders purporting to investigate potential wrongdoing by Company fiduciaries and other issues relating to the Company's statements regarding the safety of its use of EO and/or the EO tort lawsuits and other risks of its EO operations. The Company produced documents in response to the 220 Demands, and all of the shareholders have since indicated that they have completed their investigations.

**14. Financial Instruments and Financial Risk** 

***Derivative Instruments***

We do not use derivatives for trading or speculative purposes and are not a party to leveraged derivatives.

*Derivatives Designated in Hedge Relationships*

From time to time, the Company utilizes interest rate derivatives designated in hedge relationships to manage interest rate risk associated with our variable rate borrowings. These instruments are measured at fair value with changes in fair value recorded as a component of "Accumulated other comprehensive income (loss)" on our Consolidated Balance Sheets.

In March 2025, we entered into an interest rate swap agreement with a notional amount of $400.0 million. The interest rate swap was effective on August 31, 2025 and expires on August 31, 2027. We receive interest at the one-month Term SOFR rate

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

and pay a fixed interest rate under the terms of the swap agreement. In March 2023, we entered into an interest rate swap agreement with a notional amount of $400.0 million. The interest rate swap was effective on August 23, 2023 and expired on August 23, 2025. We received interest at the one-month Term SOFR rate and paid a fixed interest rate under the terms of the swap agreement.

We designated both interest rate swaps as cash flow hedges designed to hedge the variability of cash flows attributable to changes in the SOFR benchmark interest rate of our Term Loan (or any successor thereto).

*Derivatives Not Designated in Hedge Relationships*

The Company also enters into foreign currency forward contracts to manage foreign currency exchange rate risk of our intercompany loans in certain of our international subsidiaries and non-functional currency assets and liabilities. The foreign currency forward contracts expire on a monthly basis. These foreign currency derivatives are not designated in hedge relationships.

*Embedded Derivatives*

We have embedded derivatives in certain of our customer and supply contracts as a result of the currency of the contract being different from the functional currency of the parties involved. Changes in the fair value of the embedded derivatives are recognized in "Other income, net" in the Consolidated Statements of Operations and Comprehensive Income.

The following table provides a summary of the notional and fair values of our derivative instruments:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **March 31, 2026** | **December 31, 2025** | **December 31, 2025** | **December 31, 2025** |
| *<u>(in U.S. Dollars; notional in millions, fair value in thousands)</u>* |  |  | **Fair Value** | **Fair Value** |  | **Fair Value** | **Fair Value** |
|  | **Notional<br>Amount** |  | **Derivative<br>Assets** | **Derivative<br>Liabilities** | **Notional<br>Amount** | **Derivative<br>Assets** | **Derivative<br>Liabilities** |
| Derivatives designated as hedging instruments |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate swaps | **400.0** |  | **—** | **153** | 400.0 |  | 2346 |
| Derivatives not designated as hedging instruments |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contracts | **137.6** |  | **47** | **68** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Embedded derivatives | **249.5** | <sup>(a)</sup> | **1988** | **3862** | 264.4 | 1162 | 1872 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | $**787.1** |  | $**2035** | $**4083** | $664.4 | $1162 | $4218 |

---

(a)Represents the total notional amounts for certain of the Company's supply and sales contracts accounted for as embedded derivatives.

Embedded derivatives assets/liabilities and foreign currency forward contracts are included in "Prepaid expenses and other current assets" and "Accrued Liabilities" on our Consolidated Balance Sheets depending upon their position at period end. Interest rate swaps are included in "Other assets" and "Noncurrent liabilities" on the Consolidated Balance Sheets depending upon their position at period end.

The following table summarizes the activities of our derivative instruments for the periods presented, and the line item they are recorded in the Consolidated Statements of Operations and Comprehensive Income:

---

| | | |
|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* |  |  |
| **<u>Three Months Ended March 31,</u>** | **2026** | **2025** |
| Realized gain on interest rate derivatives recorded in interest expense, net<sup>(a)</sup> | **(43)** | (339) |
| Unrealized loss on embedded derivatives recorded in other income, net | **1194** | 1604 |
| Realized loss (gain) on foreign currency forward contracts recorded in foreign exchange (gain) loss | **1216** | (564) |
| Unrealized loss on foreign currency forward contracts recorded in foreign exchange (gain) loss | **21** | 440 |

---

(a)For the three months ended March 31, 2026 and 2025, amounts represent settlement payments on interest rate swaps.

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

***Credit Risk***

Certain of our financial assets, including cash and cash equivalents, are exposed to credit risk.

We are also exposed, in our normal course of business, to credit risk from our customers. As of March 31, 2026 and December 31, 2025, accounts receivable was net of an allowance for uncollectible accounts of $2.6 million and $3.0 million, respectively.

Credit risk on financial instruments arises from the potential for counterparties to default on their contractual obligations to us. We are exposed to credit risk in the event of non-performance, but do not anticipate non-performance by any of the counterparties to our financial instruments. We limit our credit risk by dealing with counterparties that are considered to be of high credit quality. In the event of non-performance by counterparties, the carrying value of our financial instruments represents the maximum amount of loss that would be incurred.

Our credit team evaluates and regularly monitors changes in the credit risk of our customers. We routinely assess the collectability of accounts receivable and maintain an adequate allowance for uncollectible accounts to address potential credit losses. The process includes a review of customer financial information and credit ratings, current market conditions as well as the expected future economic conditions that may impact the collection of trade receivables. We regularly review our customers' past due amounts through an analysis of aged accounts receivables, specific customer past due aging amounts, and the history of trade receivables written off. Upon concluding that a receivable balance is not collectible, the balance is written off against the allowance for uncollectible accounts.

***Fair Value Hierarchy***

The fair value of our financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The valuation techniques we would use to determine such fair values are described as follows: Level 1—fair values determined by inputs utilizing quoted prices in active markets for identical assets or liabilities; Level 2—fair values based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable; Level 3—fair values determined by unobservable inputs reflecting our own assumptions, consistent with reasonably available assumptions made by other market participants.

The following table discloses the fair value of our financial assets and liabilities:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **<u>As of March 31, 2026</u>** | | **Fair Value** | **Fair Value** | **Fair Value** |
| *<u>(thousands of U.S. dollars)</u>* | **Carrying<br>Amount** | **Level 1**  | **Level 2**  | **Level 3**  |
| Derivatives designated as hedging instruments<sup>(a)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate swap liabilities | $**153** | **—** | $**153** |  |
| Derivatives not designated as hedging instruments<sup>(b)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contract assets | **47** | **—** | **47** | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency forward contract liabilities | **68** | **—** | **68** | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Embedded derivative assets | **1988** | **—** | **1988** | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Embedded derivative liabilities | **3862** | **—** | **3862** | **—** |
| Current portion of long-term debt<sup>(c)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Term Loan, due 2031 | **13983** | **—** | **14230** | **—** |
| Long-Term Debt<sup>(c)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Secured Notes, due 2031 | **747015** | **—** | **776250** | **—** |
| &nbsp;&nbsp;&nbsp;&nbsp;Term Loan, due 2031 | **1377312** | **—** | **1401685** | **—** |
| Finance Lease Obligations (with current portion)<sup>(d)</sup> | **96778** | **—** | **96778** | **—** |

---

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

---

| | | | | |
|:---|:---|:---|:---|:---|
| **<u>As of December 31, 2025</u>** | | **Fair Value** | **Fair Value** | **Fair Value** |
| *<u>(thousands of U.S. dollars)</u>* | **Carrying<br>Amount** | **Level 1**  | **Level 2**  | **Level 3**  |
| Derivatives designated as hedging instruments<sup>(a)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest rate swap assets | 2346 |  | 2346 |  |
| Derivatives not designated as hedging instruments<sup>(b)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Embedded derivative assets | 1162 |  | 1162 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Embedded derivative liabilities | 1872 |  | 1872 |  |
| Current portion of long-term debt<sup>(c)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Term Loan, due 2031 | 13973 |  | $14327 |  |
| Long-Term Debt<sup>(c)</sup> |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Secured Notes, due 2031 | 746871 |  | 789375 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Term Loan, due 2031 | 1379853 |  | 1410539 |  |
| Finance Lease Obligations (with current portion)<sup>(d)</sup> | 97300 |  | 97300 |  |

---

(a)Derivatives designated as hedging instruments are measured at fair value with changes in fair value recorded as a component of accumulated other comprehensive income (loss). Interest rate swaps are valued using pricing models that incorporate observable market inputs including interest rate curves and yield curves.

(b)Derivatives that are not designated as hedging instruments are measured at fair value with gains or losses recognized immediately in the Consolidated Statements of Operations and Comprehensive Income. Embedded derivatives are valued using internally developed models that rely on observable market inputs, including foreign currency forward curves. Foreign currency forward contracts are valued by reference to changes in foreign currency exchange rate over the life of the contract.

(c)Carrying amounts of current portion of long-term debt and long-term debt instruments are reported net of discounts and debt issuance costs. The estimated fair value of these instruments are based upon quoted prices for the Term Loan and the Secured Notes in inactive markets as provided by an independent fixed income security pricing service.

(d)Fair value approximates carrying value.

**15. Segment Information** 

We identify our operating segments based on the way we manage, evaluate and internally report our business activities for purposes of allocating resources and assessing performance. We have three reportable segments: Sterigenics, Nordion and Nelson Labs. We have determined our reportable segments based upon an assessment of organizational structure, service types, and internally prepared financial statements. Our chief operating decision maker, the Chairman and Chief Executive Officer of Sotera Health Company ("CODM"), evaluates performance and allocates resources based on net revenues and segment income after the elimination of intercompany activities. The CODM uses these performance measures to inform decisions about the operations of the business and dedication of resources to selling and general administrative matters pertinent to the Company. The accounting policies of our reportable segments are the same as those described in Note 1, "Significant Accounting Policies," of the Company's annual consolidated financial statements and accompanying notes in our 2025 10-K.

*<u>Sterigenics</u>*

Sterigenics provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three major technologies: gamma irradiation, EO processing and E-beam irradiation.

*<u>Nordion</u>*

Nordion is a leading global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a leading global provider of gamma irradiation systems.

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

*<u>Nelson Labs</u>*

Nelson Labs provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** | **Three Months Ended March 31, 2026** |
| *<u>(thousands of U.S. dollars)</u>* | **Sterigenics** | **Nordion** | **Nelson Labs** | **Total** |
| Net revenues<sup>(a)</sup> | $186135 | $42009 | $51901 | $280045 |
| Segment expenses<sup>(b)</sup> | 81026 | 17018 | 36000 | 134044 |
| Corporate expense allocation<sup>(c)</sup> | 8695 | 1280 | 1373 | 11348 |
| Segment income | $**96414** | $**23711** | $**14528** | $**134653** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** | **Three Months Ended March 31, 2025** |
| *<u>(thousands of U.S. dollars)</u>* | **Sterigenics** | **Nordion** | **Nelson Labs** | **Total** |
| Net revenues<sup>(a)</sup> | $169684 | $32557 | $52282 | $254523 |
| Segment expenses<sup>(b)</sup> | 72854 | 13795 | 34552 | 121201 |
| Corporate expense allocation<sup>(c)</sup> | 8826 | 1340 | 1317 | 11483 |
| Segment income | $**88004** | $**17422** | $**16413** | $**121839** |

---

(a)Revenues are reported net of intersegment sales. Our Nordion segment recognized $19.2 million and $9.8 million in revenues from sales to our Sterigenics segment for the three months ended March 31, 2026 and 2025, respectively, that is not reflected in net revenues in the table above. Intersegment sales for Sterigenics and Nelson Labs are immaterial for all periods presented.

(b)Segment expenses are comprised of direct materials, labor, utilities, other costs of revenues, SG&A, and other non-operating expenses (income) attributable to each segment.

(c)Corporate expenses that are directly incurred by a segment are reflected in each segment's income. The remaining Corporate expenses for executive management, accounting, information technology, legal, human resources, treasury, investor relations, corporate development, tax, purchasing, and marketing not directly incurred by a segment are allocated to the segments primarily based on total net revenue.

Capital expenditures by segment for the three months ended March 31, 2026 and 2025 were as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| *<u>(thousands of U.S. dollars)</u>* | **2026** | **2025** |
| &nbsp;&nbsp;&nbsp;&nbsp;Sterigenics | $**37893** | $16395 |
| &nbsp;&nbsp;&nbsp;&nbsp;Nordion | **4288** | 2390 |
| &nbsp;&nbsp;&nbsp;&nbsp;Nelson Labs | **3985** | 1133 |
| **Total capital expenditures** | $**46166** | $19918 |

---

Total assets and depreciation and amortization expense by segment are not readily available and are not reported separately to the CODM.

------

<u>[**Table of Contents**](#i92a3125af8534be29ee40d5a2264a8b3_7)</u>

Sotera Health Company

Notes to Consolidated Financial Statements

A reconciliation of segment income to consolidated income (loss) before income taxes is as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| *(thousands of U.S. dollars)* | **2026** | **2025** |
| **Segment income** | $**134653** | $121839 |
| **Less adjustments:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | **34745** | 40876 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization<sup>(a)</sup> | **30744** | 40734 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation<sup>(b)</sup> | **14442** | 7269 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on foreign currency and derivatives not designated as hedging instruments, net<sup>(c)</sup> | **624** | 1891 |
| &nbsp;&nbsp;&nbsp;&nbsp;Business optimization expenses<sup>(d)</sup> | **957** | 2047 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional services relating to EO sterilization facilities<sup>(e)</sup> | **9855** | 12328 |
| &nbsp;&nbsp;&nbsp;&nbsp;Illinois EO litigation settlement<sup>(f)</sup> | **—** | 30943 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accretion of asset retirement obligation<sup>(g)</sup> | **673** | 574 |
| **Consolidated income (loss) before income taxes** | $**42613** | $(14823) |

---

(a)Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities.

(b)Represents share-based compensation expense to employees and Non-Employee Directors.

(c)Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.

(d)Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with secondary offerings and shareholder engagement.

(e)Represents litigation and other professional fees associated with our EO sterilization facilities.

(f)Represents the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025.

(g)Represents non-cash accretion of ARO related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*You should read the following discussion and analysis in conjunction with our consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q, as well as the audited consolidated financial statements and notes and Management's Discussion and Analysis of Financial Condition and Results of Operations contained in our 2025 Form 10-K. This discussion and analysis contains forward-looking statements that are based on management's current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements as a result of various factors, including the factors we describe in the section entitled Part II, Item 1A, "Risk Factors" in this Quarterly Report on Form 10-Q, as well as Part I, Item 1A, "Risk Factors" in our 2025 Form 10-K.*

**OVERVIEW**

We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health<sup>®</sup>. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. Our services are an essential aspect of our customers' manufacturing processes and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of these services are necessary for our customers to satisfy applicable government requirements.

We serve our customers throughout their product lifecycles, from product design to manufacturing and delivery, helping to ensure the sterility, effectiveness and safety of their products for the end user. We operate across two core businesses: sterilization services and lab services. Each of our businesses has a longstanding record and is a leader in its respective market, supported and connected by our core capabilities including deep end market, regulatory, technical and logistics expertise. The combination of Sterigenics, our terminal sterilization business, and Nordion, our Co-60 supply business, makes us the only vertically integrated global gamma sterilization provider in the sterilization industry. This provides us with additional insights and allows us to better serve our customers. For financial reporting purposes, our sterilization services business is comprised of two reportable segments, Sterigenics and Nordion, and our lab services business constitutes a third reportable segment, Nelson Labs.

For the three months ended March 31, 2026, we recorded net revenues of $280.0 million, net income of $26.6 million, Adjusted Net Income of $52.4 million and Adjusted EBITDA of $134.7 million. Adjusted Net Income and Adjusted EBITDA are financial measures not based on any standardized methodology prescribed by U.S. Generally Accepted Accounting Principles ("GAAP"). For the definition of Adjusted Net Income and Adjusted EBITDA and the reconciliation of these non-GAAP measures from net income (loss), please see "Non-GAAP Financial Measures."

**CONSOLIDATED RESULTS OF OPERATIONS** 

**Three Months Ended March 31, 2026, as compared to Three Months Ended March 31, 2025** 

The following table sets forth the components of our results of operations for the three months ended March 31, 2026 and 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* | **2026** | **2025** | $ Change | &nbsp;&nbsp;% Change |
| **Total net revenues** | $**280045** | $254523 | $25522 | 10.0% |
| **Total cost of revenues** | **132976** | 119091 | 13885 | 11.7% |
| **Net income (loss)** | **26589** | (13260) | 39849 | 300.5% |
| **Adjusted Net Income**<sup>(a)</sup> | **52366** | 39044 | 13322 | 34.1% |
| **Adjusted EBITDA**<sup>(a)</sup> | **134653** | 121839 | 12814 | 10.5% |

---

<sup>(a)</sup>Adjusted Net Income and Adjusted EBITDA are non-GAAP financial measures. For more information regarding our calculation of Adjusted Net Income and Adjusted EBITDA, including information about their limitations as tools for analysis and a reconciliation of net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP, to Adjusted Net Income and Adjusted EBITDA, please see the reconciliation included below in "Non-GAAP Financial Measures."

------

***Total Net Revenues***

The following table compares our revenues by type for the three months ended March 31, 2026 to the three months ended March 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(thousands of U.S. dollars)* |  |  |  |  |
| **<u>Net revenues for the three months ended March 31,</u>** | **2026** | **2025** | $ Change | &nbsp;&nbsp;&nbsp;&nbsp;% Change |
| Service | $**241608** | $223940 | $17668 | 7.9% |
| Product | **38437** | 30583 | 7854 | 25.7% |
| **Total net revenues** | $**280045** | $254523 | $25522 | 10.0% |

---

Net revenues were $280.0 million for the three months ended March 31, 2026, an increase of $25.5 million, or 10.0%, as compared with the three months ended March 31, 2025. Excluding the impact of foreign currency exchange rates, net revenues for the three months ended March 31, 2026 increased approximately 6.5% compared with the three months ended March 31, 2025.

*Service revenues*

Service revenues increased $17.7 million, or 7.9%, to $241.6 million for the three months ended March 31, 2026, as compared to $223.9 million for the three months ended March 31, 2025. Net service revenue growth was driven by favorable pricing in the Sterigenics and Nelson Labs segments, an increase in volume/mix in the Sterigenics and Nordion segments and a benefit from changes in foreign currency exchange rates across all segments, partially offset by a decline in volume and mix in the Nelson Labs segment.

*Product revenues* 

Product revenues increased $7.9 million, or 25.7%, to $38.4 million for the three months ended March 31, 2026, as compared to $30.6 million for the three months ended March 31, 2025. Favorable volume and mix at Nordion, which was primarily attributable to Co-60 harvest schedule timing, was the main driver of the increase in product revenues for the three months ended March 31, 2026 compared to the same period in the prior year as well as a benefit from changes in foreign currency exchange rates and favorable pricing.

***Total Cost of Revenues***

The following table compares our cost of revenues by type for the three months ended March 31, 2026 to the three months ended March 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| *(thousands of U.S. dollars)* |  |  |  |  |
| **<u>Cost of revenues for the three months ended March 31,</u>** | **2026** | **2025** | $ Change | &nbsp;&nbsp;&nbsp;&nbsp;% Change |
| Service | $**118828** | $107629 | $11199 | 10.4% |
| Product | **14148** | 11462 | 2686 | 23.4% |
| **Total cost of revenues** | $**132976** | $119091 | $13885 | 11.7% |

---

Total cost of revenues accounted for approximately 47.5% and 46.8% of our consolidated net revenues for the three months ended March 31, 2026 and 2025, respectively.

*Cost of service revenues* 

Cost of service revenues increased $11.2 million, or 10.4%, for the three months ended March 31, 2026, as compared to the three months ended March 31, 2025. The increase was driven by higher employee compensation costs, depreciation from capital assets recently placed into service, and an increase in direct material costs driven mainly by higher volumes. Changes in foreign currency exchange rates had a $3.8 million unfavorable impact to cost of service revenues for the three months ended March 31, 2026 compared to the same period in the prior year.

*Cost of product revenues* 

Cost of product revenues increased $2.7 million, or 23.4%, for the three months ended March 31, 2026, as compared to the three months ended March 31, 2025. The increase was primarily a result of higher volumes of Co-60 shipments, which resulted in increases in direct material and material transportation costs. Changes in foreign currency exchange rates had an unfavorable impact to cost of product revenues for the three months ended March 31, 2026 compared to the same period in the prior year.

------

***SG&A Expenses***

SG&A expenses increased $5.2 million, or 8.2%, for the three months ended March 31, 2026, as compared to the three months ended March 31, 2025. The increase was mainly attributable to an increase in share-based compensation expense, partially offset by a decrease in litigation and other professional services expense associated with EO sterilization facilities.

***Amortization of intangible assets***

Amortization of intangible assets decreased $12.3 million, or 80.2% for the three months ended March 31, 2026, as compared to the three months ended March 31, 2025. The decline was primarily due to certain intangible assets that were fully amortized in May 2025.

***Illinois EO litigation settlement***

On April 3, 2025, the Company agreed to resolve 97 pending and threatened EO claims in the State of Illinois. Pursuant to the terms of the term sheet, the Company agreed to pay $30.9 million to settle the claims.

***Interest Expense, Net***

Interest expense, net decreased $6.1 million, or 15.0%, for the three months ended March 31, 2026, as compared to the three months ended March 31, 2025, primarily due to a lower variable interest rate on our Term Loan and a $75.0 million principal paydown. The weighted average interest rate on our outstanding debt for the three months ended March 31, 2026 and March 31, 2025 was 6.62% and 7.56%, respectively.

***Foreign Exchange (Gain) Loss***

Foreign exchange gain was $0.6 million for the three months ended March 31, 2026 compared to a loss of $0.3 million for the three months ended March 31, 2025. The change in foreign exchange (gain) loss mainly relates to short-term gains and losses on transactions denominated in currencies other than the functional currency of our operating entities.

***Other Income, Net***

Other income, net increased $0.7 million for the three months ended March 31, 2026 as compared to the three months ended March 31, 2025. The increase was a result of a more favorable change in the fair value of embedded derivatives in the Nordion segment compared to the same period in the prior year and an increase in pension income in the Nordion segment.

***Provision (Benefit) for Income Taxes***

The Company recognized a $16.0 million provision for income taxes for the three months ended March 31, 2026, as compared to a $1.6 million income tax benefit for the three months ended March 31, 2025. The change was primarily attributable to pre-tax income for the three months ended March 31, 2026 compared to pre-tax loss for the three months ended March 31, 2025, partially offset by a decrease in the impact of the valuation allowance attributable to the limitation on the deductibility of interest expense.

Provision for income taxes for the three months ended March 31, 2026 differed from the statutory rate primarily due to the foreign rate differential, current year permanent differences, including foreign withholding taxes and other non-deductible items, and U.S. state income taxes (net of federal tax benefit). Provision for income taxes for the three months ended March 31, 2025 differed from the statutory rate primarily due to current year permanent differences, partially offset by the valuation allowance attributable to the limitation on the deductibility of interest expense and the impact of the foreign rate differential.

***Net Income (Loss), Adjusted Net Income and Adjusted EBITDA***

Net income for the three months ended March 31, 2026 was $26.6 million, as compared to a net loss of $13.3 million for the three months ended March 31, 2025. Adjusted Net Income was $52.4 million for the three months ended March 31, 2026, as compared to $39.0 million for the three months ended March 31, 2025, due to the factors described above. Adjusted EBITDA was $134.7 million for the three months ended March 31, 2026, as compared to $121.8 million for the three months ended March 31, 2025, due to the factors described above. Please see "Non-GAAP Financial Measures" below for a reconciliation of Adjusted Net Income and Adjusted EBITDA to their most directly comparable financial measure calculated and presented in accordance with GAAP.

**NON-GAAP FINANCIAL MEASURES**

To supplement our consolidated financial statements presented in accordance with GAAP, we consider Adjusted Net Income and Adjusted EBITDA, financial measures that are not based on any standardized methodology prescribed by GAAP.

------

We define Adjusted Net Income as net income before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period as discussed further below. We define Adjusted EBITDA as Adjusted Net Income before interest expense, depreciation (including depreciation of Co-60 used in our operations) and income tax provision applicable to Adjusted Net Income.

We use Adjusted Net Income and Adjusted EBITDA, non-GAAP financial measures, as the principal measures of our operating performance. Management believes Adjusted Net Income and Adjusted EBITDA are useful because they allow management to more effectively evaluate our operating performance and compare the results of our operations from period to period without the impact of certain non-cash items and non-routine items that we do not expect to continue at the same level in the future and other items that are not core to our operations. We believe that these measures are useful to our investors because they provide a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. In addition, we believe Adjusted Net Income and Adjusted EBITDA will assist investors in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. Our management also uses Adjusted Net Income and Adjusted EBITDA in its financial analysis and operational decision-making, and Adjusted EBITDA serves as the basis for the metric we utilize to determine attainment of our primary annual incentive program. Adjusted Net Income and Adjusted EBITDA may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

Adjusted Net Income and Adjusted EBITDA should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. There are a number of limitations related to the use of Adjusted Net Income and Adjusted EBITDA rather than net income (loss), the nearest GAAP equivalent. For example, Adjusted Net Income and Adjusted EBITDA primarily exclude:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• certain recurring non-cash charges such as depreciation of fixed assets, although these assets may have to be replaced in the future, as well as amortization of acquired intangible assets and asset retirement obligations ("ARO");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• costs of acquiring and integrating businesses, which will continue to be a part of our growth strategy;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• non-cash gains or losses from fluctuations in foreign currency exchange rates, and the mark-to-fair value of derivatives not designated as hedging instruments, which includes the embedded derivatives relating to certain customer and supply contracts at Nordion;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• impairment charges on long-lived assets, intangible assets and investments accounted for under the equity method;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• loss on refinancing of debt incurred in connection with refinancing or early extinguishment of long-term debt;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expenses incurred in connection with the secondary offering of our common stock and other shareholder activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• expenses and charges related to the litigation, settlement agreements, and other activities associated with our EO sterilization facilities, including those related to Willowbrook, Illinois, Atlanta, Georgia, Santa Teresa, New Mexico and Vernon, California;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• in the case of Adjusted EBITDA, interest expense or the cash requirements necessary to service interest or principal payments on our indebtedness; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• share-based compensation expense, which has been, and will continue to be for the foreseeable future, a significant recurring expense and an important part of our compensation strategy.

In evaluating Adjusted Net Income and Adjusted EBITDA, you should be aware that in the future, we will incur expenses similar to the adjustments in this presentation. Our presentations of Adjusted Net Income and Adjusted EBITDA should not be construed as suggesting that our future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating our performance, you should consider Adjusted Net Income and Adjusted EBITDA alongside other financial performance measures, including our net income (loss) and other GAAP measures.

------

The following table presents a reconciliation of net income (loss), the most directly comparable financial measure calculated and presented in accordance with GAAP to Adjusted Net Income and Adjusted EBITDA, for each of the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| *(thousands of U.S. dollars)* | **2026** | **2025** |
| **Net income (loss)** | $**26589** | $(13260) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | **5602** | 18674 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation<sup>(a)</sup> | **14442** | 7269 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on foreign currency and derivatives not designated as hedging instruments, net<sup>(b)</sup> | **624** | 1891 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business optimization expenses<sup>(c)</sup> | **957** | 2047 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Professional services relating to EO sterilization facilities<sup>(d)</sup> | **9855** | 12328 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Illinois EO litigation settlement<sup>(e)</sup> | **—** | 30943 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of asset retirement obligations<sup>(f)</sup> | **673** | 574 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax benefit associated with pre-tax adjustments<sup>(g)</sup> | **(6376)** | (21422) |
| **Adjusted Net Income** | **52366** | 39044 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | **34745** | 40876 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation<sup>(h)</sup> | **25142** | 22060 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax provision applicable to Adjusted Net Income<sup>(i)</sup> | **22400** | 19859 |
| **Adjusted EBITDA**<sup>(j)</sup> | $**134653** | $121839 |

---

(a)&nbsp;&nbsp;&nbsp;&nbsp;Represents share-based compensation expense to employees and Non-Employee Directors.

(b)&nbsp;&nbsp;&nbsp;&nbsp;Represents the effects of (i) fluctuations in foreign currency exchange rates and (ii) non-cash mark-to-fair value of embedded derivatives relating to certain customer and supply contracts at Nordion.

(c)&nbsp;&nbsp;&nbsp;&nbsp;Represents (i) certain costs related to divestitures, acquisitions and the integration of acquisitions, (ii) professional fees and other costs associated with business optimization, cost saving and other process enhancement projects, and (iii) legal, consulting, and other fees associated with secondary offerings and shareholder engagement.

(d)&nbsp;&nbsp;&nbsp;&nbsp;Represents litigation and other professional fees associated with our EO sterilization facilities.

(e)&nbsp;&nbsp;&nbsp;&nbsp;Represents the cost to settle 97 pending and threatened EO claims against Sterigenics in Illinois pursuant to the term sheet entered into on April 3, 2025.

(f)&nbsp;&nbsp;&nbsp;&nbsp;Represents non-cash accretion of ARO related to Co-60 gamma and EO processing facilities, which are based on estimated site remediation costs for any future decommissioning of these facilities and are accreted over the life of the asset.

(g)&nbsp;&nbsp;&nbsp;&nbsp;Represents the income tax impact of adjustments calculated based on the tax rate applicable to each item. We eliminate the effect of tax rate changes as applied to tax assets and liabilities and unusual items from our presentation of adjusted net income.

(h)&nbsp;&nbsp;&nbsp;&nbsp;Includes depreciation of Co-60 held at gamma irradiation sites and excludes accelerated depreciation associated with business optimization activities.

(i)&nbsp;&nbsp;&nbsp;&nbsp;Represents the difference between the income tax provision as determined under U.S. GAAP and the income tax benefit associated with pre-tax adjustments described in footnote (g).

(j)&nbsp;&nbsp;&nbsp;&nbsp;$26.3 million and $24.2 million of the adjustments for the three months ended March 31, 2026 and 2025, respectively, are included in cost of revenues, primarily consisting of amortization of intangible assets, depreciation, and accretion of asset retirement obligations.

**SEGMENT RESULTS OF OPERATIONS**

We have three reportable segments: Sterigenics, Nordion and Nelson Labs. Our chief operating decision maker evaluates performance and allocates resources within our business based on segment income, which excludes certain items which are included in income (loss) before tax as determined in our Consolidated Statements of Operations and Comprehensive Income. The accounting policies for our reportable segments are the same as those for the consolidated Company.

------

**Our Segments** 

***Sterigenics***

Sterigenics provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets using three major technologies: gamma irradiation, EO processing and E-beam irradiation.

***Nordion***

Our Nordion business is a leading global provider of Co-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. In addition, Nordion is a leading global provider of gamma irradiation systems.

As a result of the time required to meet regulatory and logistics requirements for delivery of radioactive products, combined with accommodations that we make to our customers to minimize disruptions to their operations during the installation of Co-60, Nordion sales patterns can often vary significantly from one quarter to the next. In most cases, however, timing-related impacts on our sales performance tend to be resolved within several quarters, resulting in more consistent performance over longer periods of time. In addition, sales of gamma irradiation systems occur infrequently and tend to be for larger amounts. Nordion's results of operations are also impacted by Co-60 harvest schedules.

***Nelson Labs***

Our Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries.

For more information regarding our reportable segments please refer to Note 15, "Segment Information" to our consolidated financial statements.

**Segment Results for the Three Months Ended March 31, 2026 and 2025** 

The following tables compare segment net revenue and segment income for the three months ended March 31, 2026 to the three months ended March 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | | |
| *(thousands of U.S. dollars)* | **2026** | **2025** | **$ Change**  | **% Change**  |
| **Net Revenues** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sterigenics | $**186135** | $169684 | $16451 | 9.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nordion | **42009** | 32557 | 9452 | 29.0% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nelson Labs | **51901** | 52282 | (381) | (0.7)% |
| **Segment Income** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sterigenics | $**96414** | $88004 | $8410 | 9.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nordion | **23711** | 17422 | 6289 | 36.1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nelson Labs | **14528** | 16413 | (1885) | (11.5)% |
| **Segment Income margin** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sterigenics | **51.8%** | 51.9% |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nordion | **56.4%** | 53.5% |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nelson Labs | **28.0%** | 31.4% |  |  |

---

*Net Revenues by Segment*

Sterigenics net revenues were $186.1 million for the three months ended March 31, 2026, an increase of $16.5 million, or 9.7%, as compared to the three months ended March 31, 2025. The increase was driven by a favorable impact from pricing of 4.5%, a favorable impact from changes in foreign currency exchange rates of 3.6% and an increase in volume/mix of 1.6%.

Nordion net revenues were $42.0 million for the three months ended March 31, 2026, an increase of $9.5 million, or 29.0%, as compared to the three months ended March 31, 2025. Revenue growth was driven mainly by volume and mix of 23.7%, which was largely attributable to favorable Co-60 harvest schedule timing, coupled with a favorable impact from changes in foreign currency exchange rates and pricing of 3.2% and 2.1%, respectively.

------

Nelson Labs net revenues were $51.9 million for the three months ended March 31, 2026, a decrease of $0.4 million, or 0.7%, as compared to the three months ended March 31, 2025. The decrease in net revenues was due to an unfavorable change in volume and mix of 6.6% offset by a benefit from changes in foreign currency exchange rates and pricing of 3.1% and 2.8%, respectively.

*Segment Income* 

Sterigenics segment income was $96.4 million for the three months ended March 31, 2026, an increase of $8.4 million, or 9.6%, as compared to the three months ended March 31, 2025. Segment income increased primarily due to a benefit from pricing, favorable changes in foreign currency exchange rates and an increase in volume/mix, partially offset by higher costs.

Nordion segment income was $23.7 million for the three months ended March 31, 2026, an increase of $6.3 million, or 36.1%, as compared to the three months ended March 31, 2025. The increase in segment income and segment income margin was primarily driven by higher volume and mix due to favorable Co-60 harvest schedule timing, along with favorable changes in pricing and foreign currency exchange rates, partially offset by inflation.

Nelson Labs segment income was $14.5 million for the three months ended March 31, 2026, a decrease of $1.9 million, or 11.5%, as compared to the three months ended March 31, 2025. The decrease in segment income and segment income margin was attributable to lower volume/mix, partially offset by a favorable impact from pricing and changes in foreign currency exchange rates.

**LIQUIDITY AND CAPITAL RESOURCES** 

**Sources of Cash**

The primary sources of liquidity for our business are cash flows from operations and borrowings under our credit facilities. As of March 31, 2026, we had $315.9 million of cash and cash equivalents, a decrease of $30.5 million from the balance at December 31, 2025. The decrease in cash and cash equivalents was mainly attributable to the $34.0 million payment for the July 2025 Illinois EO litigation settlement, $46.2 million of cash paid for purchases of property, plant and equipment and $12.8 million of cash used in financing activities. This was partially offset by $63.4 million of cash flows provided by operating activities exclusive of the Illinois EO litigation settlement payment. Our foreign subsidiaries held cash of approximately $282.0 million at March 31, 2026 and $253.4 million at December 31, 2025. No material restrictions exist to accessing cash held by our foreign subsidiaries notwithstanding any potential tax consequences.

**Uses of Cash**

We expect that cash on hand, operating cash flows and amounts available under our credit facilities will provide sufficient working capital to operate our business, meet foreseeable liquidity requirements (inclusive of debt service on our long-term debt), make expected capital expenditures including investments in fixed assets to build and/or expand existing facilities, and meet litigation costs that we expect to continue to incur for at least the next twelve months and the foreseeable future thereafter. Our primary long-term liquidity requirements beyond the next 12 months will be to service our debt, make capital expenditures, and fund suitable business acquisitions. As of March 31, 2026, there were no outstanding borrowings on the Revolving Credit Facility. We expect any excess cash provided by operations will be allocated to fund capital expenditures, potential acquisitions, or for other general corporate purposes. Our ability to meet future working capital, capital expenditures and debt service requirements will depend on our future financial performance, which will be affected by a range of macroeconomic, competitive and business factors, including interest rate changes and changes in our industry, many of which are outside of our control.

**Capital Expenditures**

Our capital expenditure program is a component of our long-term strategy. This program includes, among other things, investments in new and existing facilities, business expansion projects, Co-60 used by Sterigenics at its gamma irradiation facilities, cobalt development projects and information technology enhancements. During the three months ended March 31, 2026, our capital expenditures amounted to $46.2 million, compared to $19.9 million for the three months ended March 31, 2025.

------

**Cash Flow Information**

***Three Months Ended March 31, 2026 compared to the Three Months Ended March 31, 2025*** 

---

| | | |
|:---|:---|:---|
| *<u>(thousands of U.S. dollars)</u>* | **2026** | **2025** |
| Net Cash Provided by (Used in): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating activities | $**29435** | $55521 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing activities | **(45128)** | (19881) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing activities | **(12779)** | (8087) |
| Effect of foreign currency exchange rate changes on cash and cash equivalents | **(2039)** | (337) |
| **Net (decrease) increase in cash and cash equivalents, including restricted cash, during the period** | $**(30511)** | $27216 |

---

*Operating activities* 

Cash flows provided by operating activities decreased $26.1 million to net cash provided of $29.4 million for the three months ended March 31, 2026 compared to $55.5 million for the three months ended March 31, 2025. The decrease in cash flows provided by operating activities for the three months ended March 31, 2026 compared to the three months ended March 31, 2025 was primarily driven by the $34.0 million payment of the Illinois EO litigation settlement, partially offset by a $10.9 million decrease in cash paid for interest.

*Investing activities* 

Cash used in investing activities increased $25.2 million to net cash used of $45.1 million for the three months ended March 31, 2026 compared to $19.9 million for the three months ended March 31, 2025. The variance was mainly driven by an increase in capital expenditures of $26.2 million for the three months ended March 31, 2026 compared to the three months ended March 31, 2025.

*Financing activities* 

Cash used in financing activities increased by $4.7 million to $12.8 million for the three months ended March 31, 2026 compared to $8.1 million for the three months ended March 31, 2025. The difference was due mainly to a $5.2 million increase in cash flows used in shares withheld for employee taxes on equity awards.

**Debt Facilities**

On December 13, 2019, SHH, our wholly owned subsidiary, entered into the Senior Secured Credit Facilities consisting of both the Term Loan and the Revolving Credit Facility pursuant to a first lien credit agreement. The total borrowing capacity under the Revolving Credit Facility is $600.0 million. The Senior Secured Credit Facilities also provide SHH the right at any time and under certain conditions to request incremental term loans or incremental revolving credit commitments based on a formula defined in the Senior Secured Credit Facilities.

On May 30, 2024, SHH, the Company, certain subsidiaries of the Company, and Wilmington Trust, National Association, as trustee, paying agent, registrar, transfer agent and notes collateral agent, entered into an Indenture (the "Indenture") governing SHH's $750.0 million aggregate principal amount of 7.375% senior secured notes due 2031 (the "Secured Notes") issued in May 2024.

The Senior Secured Credit Facilities and the Indenture contain certain covenants and events of default. Additionally, all of SHH's obligations under the Senior Secured Credit Facilities and the Indenture are unconditionally guaranteed by the Company and certain domestic restricted subsidiaries. For additional information about our Senior Secured Credit Facilities, the Indenture and the Secured Notes, including the covenants and events of default, refer to Note 8, "Long-Term Debt," to our Financial Statements.

Outstanding letters of credit are collateralized by encumbrances against the Revolving Credit Facility and the collateral pledged thereunder, or by cash placed on deposit with the issuing bank. As of March 31, 2026, the Company had $8.3 million of letters of credit issued against the Revolving Credit Facility, resulting in total availability under the Revolving Credit Facility of $591.7 million.

------

*Term Loan Interest Rate Risk Management*

The Company utilizes interest rate derivatives to reduce the variability of cash flows in the interest payments associated with our variable rate debt due to changes in SOFR. For additional information on the derivative instruments described above, refer to Note 14, "Financial Instruments and Financial Risk – Derivative Instruments*."*

**CRITICAL ACCOUNTING POLICIES AND ESTIMATES** 

The preparation of consolidated financial statements and related disclosures in conformity with GAAP requires management to make judgments, estimates and assumptions at a specific point in time and in certain circumstances that affect amounts reported in the accompanying consolidated financial statements. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts, giving due consideration to materiality. The application of accounting policies involves the exercise of judgment and use of assumptions as to future uncertainties and, as a result, actual results could differ from these estimates.

A comprehensive discussion of the Company's critical accounting policies and management estimates made in connection with the preparation of the financial statements is included in Item 7 of our 2025 Form 10-K. There have been no significant changes in critical accounting policies, management estimates or accounting policies since the year ended December 31, 2025.

**NEW ACCOUNTING PRONOUNCEMENTS** 

For a description of recent accounting pronouncements applicable to our business, see Note 2, "Recent Accounting Standards," to our consolidated financial statements.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Market risks are described within "Quantitative and Qualitative Disclosures About Market Risk" in Part II, Item 7A of our 2025 Form 10-K. These market risks have not materially changed for the three months ended March 31, 2026.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's "disclosure controls and procedures," (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based upon their evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (the "SEC"), and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

**Changes in Internal Control**

During the three months ended March 31, 2026, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

------

**Part II—OTHER INFORMATION**

**Item 1. Legal Proceedings.**

From time to time, we may be subject to various legal proceedings arising in the ordinary course of our business, including claims relating to personal injury, property damage, workers' compensation, employee safety and our disclosures as a Nasdaq-listed, publicly-traded company. In addition, from time to time, we receive communications from government or regulatory agencies concerning investigations or allegations of noncompliance with laws or regulations in jurisdictions in which we operate. At this time, and except as disclosed herein, we are unable to predict the outcome of, and cannot reasonably estimate the impact of, any pending litigation matters, matters concerning allegations of non-compliance with laws or regulations and matters concerning other allegations of other improprieties, or the incidence of any such matters in the future. Information regarding our legal proceedings is included below.

**Legal Proceedings Described in Note 13 "Commitments and Contingencies," of Our Consolidated Financial Statements** 

Note 13, "Commitments and Contingencies," to our consolidated financial statements for the three months ended March 31, 2026 contained in this Quarterly Report on Form 10-Q includes information on legal proceedings that constitute material contingencies for financial reporting purposes that could have a material effect on our financial condition or results of operations. This Item should be read in conjunction with Note 13 "Commitments and Contingencies," for information regarding the following legal proceedings, which information is incorporated into this Item 1 by reference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ethylene Oxide Tort Litigation – California, Georgia, Illinois and New Mexico;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Insurance Coverage for Environmental Liabilities; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Sotera Health Company Securities Litigation and Related Matters.

**Legal Proceedings Not Described in Note 13 "Commitments and Contingencies," to Our Consolidated Financial Statements**

In addition to the matters identified in Note 13 "Commitments and Contingencies," to our consolidated financial statements for the three months ended March 31, 2026 contained in this Quarterly Report on Form 10-Q, and incorporated into this item by reference, we report matters, if any, that constitute material pending legal proceedings, other than ordinary course litigation incidental to our business, to which we are or any of our subsidiaries is a party. SEC regulations require disclosure of environmental proceedings that involve a government authority and potential monetary sanctions that the Company reasonably believes will exceed a specified threshold. The Company uses a threshold of $1.0 million to determine whether the disclosure of any such proceedings is required because we believe matters under this threshold are not material to the Company.

**Item 1A. Risk Factors.** 

There have been no material changes from the risk factors previously described under Item 1A of our 2025 Form 10-K.

**Item 5. Other Information.** 

*Rule 10b5-1 Trading Plans*

During the three months ended March 31, 2026, none of the Company's directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any "non-Rule 10b5-1 trading arrangement" (as that term is defined in Regulation S-K, Item 408).

------

**Item 6. Exhibits.**

The exhibits listed in the following Exhibit Index are filed, furnished, or incorporated by reference as part of this Quarterly Report on Form 10-Q.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| **Exhibit No** | **Description of Exhibits** | **Form** | **File No.** | **Exhibit** | **Filing Date** | **Furnished/Filed <br>Herewith** |
| **Exhibit No** | **Description of Exhibits** | **Form** | **File No.** | **Exhibit** | **Filing Date** | **Furnished/Filed <br>Herewith** |
| 10.1 | <u>[Advisory Agreement dated as of April 1, 2026, by and between Alexander Dimitrief and Sotera Health Company](shc20260331_exhibitx10x1.htm)</u> |  |  |  |  | \* |
| 10.2 | <u>[Advisory Agreement Amendment dated as of April 17, 2026, by and among Dimitrief Advisory LLC, Alexander Dimitrief and Sotera Health Company](shc20260331_exhibitx10x2.htm)</u> |  |  |  |  | \* |
| 31.1 | <u>[Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](shc_20260331xexhibitx31x1.htm)</u> |  |  |  |  | \* |
| 31.2 | <u>[Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](shc20260331_exhibitx31x2.htm)</u> |  |  |  |  | \* |
| 32.1 | <u>[Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](shc20260331_exhibitx32x1.htm)</u>  |  |  |  |  | \*\* |
| 101.INS | Inline XBRL Instance Document - The XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |  |  |  |  | \* |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  | \* |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  | \* |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |  | \* |
| 101.LAB | Inline XBRL Taxonomy Label Linkbase Document |  |  |  |  | \* |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document  |  |  |  |  | \* |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |  |  |  |  | \* |

---

\*&nbsp;&nbsp;&nbsp;&nbsp;Filed Herewith

\*\*&nbsp;&nbsp;&nbsp;&nbsp;Furnished Herewith

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| SOTERA HEALTH COMPANY | SOTERA HEALTH COMPANY |
| By: | /s/ Jonathan M. Lyons |
| Name: | Jonathan M. Lyons |
| Title: | Senior Vice President and Chief Financial Officer |
|  | (Principal Financial Officer) |

---

Date: May 5, 2026

## Exhibit 10.1

**Exhibit 10.1**

**ADVISORY AGREEMENT**

This Advisory Agreement (the "***Agreement***"), dated as of the date of the last signature to this Agreement and effective as of April 1, 2026 (the "***Effective Date***"), is entered into by and between Alexander Dimitrief (the "***Advisor***") and Sotera Health Company (the "***Company***"). Each of the Advisor and the Company is hereby a "***Party***" to this Agreement (together, they are the "***Parties***" to this Agreement).

**WHEREAS**, the Advisor is currently an employee and executive officer of the Company, but the Advisor intends to retire from the Company and terminate his employment with the Company and its subsidiaries and affiliates (the "***Company Group***") on the Effective Date ("***Retirement***");

**WHEREAS**, the Company and its Board of Directors (the "***Board***") wish to benefit from certain skills and abilities of the Advisor following the Advisor's Retirement;

**WHEREAS**, after his Retirement, and starting on the Effective Date, the Advisor will be ready and willing to provide advisory services to the Company; and

**WHEREAS**, during the period when the Advisor provides such advisory services to the Company, the Advisor will be provided with access to trade secrets and confidential information of the Company Group.

**NOW, THEREFORE**, in consideration of the terms and conditions and mutual promises set forth or described in this Agreement, and other good and valuable consideration, the receipt by the Parties and the sufficiency and adequacy of which are hereby acknowledged by such Parties, the Company and the Advisor hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>SERVICES</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.The Advisor agrees to provide to the Company advisory services (specifically involving or relating to supporting and performing various tasks and responsibilities related to ethylene oxide litigation support (including attending litigation committee meetings)) (the "***Services***"), on the terms and conditions set forth in this Agreement, during the Term (as defined in **<u>Section 8</u>**). In the provision of the Services, the Advisor shall provide the Services during such hours as may be mutually agreed upon by the Parties, with no implied minimum service requirement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.The Advisor shall be solely responsible for, and shall have sole control over, the means, methods, techniques, sequences, and procedures used in providing the Services. The Company Group shall provide the Advisor with access to its premises, materials, information, and systems to the extent necessary for the performance of the Services.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.The Parties agree that, based on the expected service requirement under this Agreement, upon the Advisor's Retirement, the Advisor will have experienced a "separation from service" within the meaning of Treasury Regulation 1.409A-1(h).

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>ADVISORY COMPENSATION</u>. The Company shall compensate the Advisor for the Services with a fixed monthly fee of $22,500, payable for each month during the Term in arrears, exclusive of any actual, reasonable, and documented out-of-pocket fees or expenses incurred in connection with providing the Services ("***Expenses***"), with each such payment made within five business days of the last business day of each month during the Term (the "***Advisory Fee***"). If the Advisor does not provide the Services for any period, then the Advisor shall not be entitled to receive any Advisory Fee for such period. The Advisor will not be eligible to participate in any benefit plan offered by the Company Group to their employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>EXPENSES</u>. The Company agrees to reimburse the Advisor for Expenses. All undisputed Expenses will be paid within 30 days of the Company's receipt of the documents evidencing such Expenses. If any reimbursement provided by the Company pursuant to this Agreement would constitute deferred compensation for purposes of Section 409A of the Internal Revenue Code of 1986, as amended, such reimbursement shall be subject to the following rules: (A) the amount eligible for reimbursement during any calendar year may not affect the expenses eligible for reimbursement, or the in-kind benefits provided, in any other calendar year; (B) any reimbursement shall be made on or before the last day of the calendar year following the calendar year in which the expense was incurred; and (C) the Advisor's right to reimbursement is not subject to liquidation or exchange for cash or another benefit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.<u>WITHHOLDING</u>. The Advisor acknowledges that the Advisor will be solely responsible to pay all taxes that may be imposed on the Advisor as a result of the compensation under this Agreement, including the timely payment of estimated tax payments. The Advisor also acknowledges and agrees that, during the Term, the Advisor will not be treated as an employee of the Company Group for purposes of federal, state, local or foreign income tax withholding, or, unless otherwise specifically provided by law, for purposes of the Federal Insurance Contributions Act, the Social Security Act, the Federal Unemployment Tax Act or any worker's compensation law of any state or country and for purposes of benefits provided to employees of the Company Group under any employee benefit plan. The Company Group has not made any representations or guarantees regarding the tax result for the Advisor with respect to any income recognized by the Advisor in connection with this Agreement or any amounts payable under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.<u>CONFIDENTIALITY</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.During and following the term of this Agreement, the Advisor will keep confidential all Confidential Information (defined below) of the Company Group, as applicable, use such Confidential Information solely in connection with providing the Services and not disclose any such Confidential Information to any other person other than the Company Group, except to the extent disclosure is required by law. "***Confidential Information***" means all information relating to the business, operations, assets, liabilities, plans, prospects and affairs regarding the Company Group, that is disclosed to the Advisor, regardless of whether such information is in oral, visual, electronic, written, or other form and whether or not it is identified as "confidential." Confidential Information does not include any information that is or becomes generally available to the public other than as a result of disclosure by the Advisor or is or becomes available to the Advisor on a non-confidential basis by any person who is not bound by any obligation to keep such information confidential.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.Further, nothing in this Agreement, nor any Company policy or individual agreement between the Company and the Advisor, prevents the Advisor from providing, without prior notice to the Company, information to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or proceeding by any governmental authorities regarding possible legal violations (including the Company's past or future conduct), engaging in any future activities protected under the whistleblower statutes administered by any government agency (*e.g.*, EEOC, NLRB, SEC, etc.), or receiving a monetary award from a government-administered whistleblower award program for providing information directly to a government agency. The Company nonetheless asserts and does not waive its attorney-client privilege over any information appropriately protected by privilege.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.The U.S. Defend Trade Secrets Act of 2016 ("***DTSA***") provides that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i) is made (a) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and (b) solely for the purpose of reporting or investigating a suspected violation of law, or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, the DTSA provides that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (x) files any document containing the trade secret under seal and (y) does not disclose the trade secret, except pursuant to court order.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D.The Company will take reasonable steps to provide confidential treatment that is reasonably comparable to that described in this **<u>Section 5</u>** for any confidential information of the Advisor that is actually received by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.<u>ADHERENCE TO POLICIES</u>. The Advisor will provide the Services in a manner consistent with the Company's applicable policies (collectively such policies, the "***Policies***") that are reasonably known to (or should be known to) the Advisor or about which the Advisor is reasonably aware (or should be reasonably aware) as of the Effective Date. The Advisor shall disclose to the Company any work that the Advisor plans to undertake for other parties relating to ethylene oxide and comply with reasonable requests by the Company for additional information related to any such work. If the Company determines that any such work poses an unacceptable conflict of interest, the Company, as its exclusive remedy upon such a determination, may terminate this Agreement with immediate effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.<u>INDEMNIFICATION</u>. The Company shall indemnify the Advisor if the Advisor is made, or threatened to be made, a party to any litigation (including all related discovery) or investigation by a government agency because of the Advisor's provision of the Services to the Company on or after the Effective Date (other than proceedings relating to the Advisor's alleged failure to pay taxes related to the Advisor's compensation under this Agreement). Pursuant to this **<u>Section 7</u>**, the Advisor shall be indemnified to the fullest extent permitted by applicable law against all expenses, judgments, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such expenses, judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by the Advisor or on his behalf. This provision is intended to provide the Advisor with

------

indemnification to the fullest extent permitted by law and to continue in its entirety the indemnification to which the Advisor was entitled as an officer of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.<u>TERM AND TERMINATION</u>. This Agreement takes effect on the Effective Date and shall continue thereafter through March 31, 2027, unless terminated in accordance with the provisions herein (the "***Term***"). Any extension of the Term will be subject to mutual written agreement between the Company and the Advisor. This Agreement may be terminated by the Company or the Advisor for any reason, effective upon 30 days' written notice to the other Party, except as otherwise provided in **<u>Section 6</u>** of this Agreement. No further Advisory Fee shall be due or payable to the Advisor if the Agreement is terminated. Upon expiration or termination of this Agreement, or at any other time upon the Company's written request, the Advisor shall promptly deliver to the Company all materials containing, reflecting, incorporating or based on Confidential Information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.<u>INDEPENDENT CONTRACTOR</u>. The Advisor is providing the Services pursuant to this Agreement as an independent contractor to the Company, and, as of the Effective Date, the Advisor will not be an employee of the Company or any of its affiliates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.<u>AMENDMENT; WAIVER</u>. Any provision of this Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by each of the Advisor and the Company. Nothing in this Agreement shall be binding upon the Parties to this Agreement to the extent it is void or unenforceable for any reason, including, without limitation, as a result of any law regulating competition or proscribing unlawful business practices; <u>provided</u>, <u>however</u>, that to the extent that any provision in this Agreement could be modified to render it enforceable under applicable law, it shall be deemed so modified and enforced to the fullest extent allowed by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.<u>GOVERNING LAW</u>. All issues and questions concerning the construction, validity, interpretation and enforceability of this Agreement, including any claims relating to or arising out of this Agreement, shall be governed by and construed in accordance with the laws of the State of Ohio without regard to its conflict of laws principles.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.<u>COMPLETE AGREEMENT; SURVIVABILITY</u>. This Agreement embodies the complete agreement and understanding between the Company and the Advisor with respect to the subject matter hereof and supersedes and preempts any prior understandings, agreements, or representations by or between the Parties, written or oral, that may have related to the subject matter hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.<u>ASSIGNMENT</u>. The Parties shall not assign their rights under this Agreement without the other Party's prior written consent, and the Advisor shall not permit the Services to be performed by someone other than the Advisor, provided that, if the Advisor elects to form a Limited Liability Company, the Advisor may assign this Agreement to the Limited Liability Company, subject to the LLC's agreement that the Services will continue to be provided exclusively by the Advisor. Subject to the limits on assignment stated above, this Agreement will inure to the benefit of, be binding on, and be enforceable against each of the Parties hereto and their respective successors.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.<u>NOTICES</u>. All notices, requests, consents, claims, demands, waivers, and other communications hereunder (each, a "***Notice***") shall be in writing and addressed to the Parties, including to the address most recently on file with the Company if to the Advisor (or to such other address that may be designated by the receiving Party from time to time in accordance with this Section). All Notices shall be delivered by personal delivery, nationally recognized overnight courier (with all fees prepaid), email, facsimile (with confirmation of transmission), or certified or registered mail (in each case, return receipt requested, postage prepaid). Except as otherwise provided in this Agreement, a Notice is effective only if the receiving Party has received the Notice, and the Party giving the Notice has complied with the requirements of this Section.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.<u>COUNTERPARTS</u>. This Agreement may be executed in multiple counterparts and by electronic signature, each of which shall be deemed an original and all of which together shall constitute one instrument.

&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the Parties have executed this Agreement to be effective as of the Effective Date.

---

| |
|:---|
| **SOTERA HEALTH COMPANY** |
| /s/ Michael B. Petras, Jr. |
| Name: Michael B. Petras, Jr. |
| Title: Chief Executive Officer |
| **ADVISOR** |
| /s/ Alexander Dimitrief |
| Name: Alexander Dimitrief |

---

## Exhibit 10.2

**Exhibit 10.2**

**ADVISORY AGREEMENT AMENDMENT**

This Advisory Agreement Amendment (the "***Amendment***"), dated as of the date of the last signature to this Amendment and effective as of April 17, 2026 (the "***Amendment Effective Date***"), is entered into by and among Dimitrief Advisory LLC (the "***Consulting LLC***"), Alexander Dimitrief ("***Dimitrief***") and Sotera Health Company (the "***Company***"). Each of the Consulting LLC, the Advisor and the Company is hereby a "***Party***" to this Amendment (together, they are the "***Parties***" to this Amendment).

**WHEREAS**, Dimitrief and the Company are currently parties to an Advisory Agreement, dated and effective as of April 1, 2026 (the "***Agreement Effective Date***") (such Advisory Agreement, the "***Agreement***"), pursuant to which Dimitrief and the Company agreed to certain terms and conditions regarding Dimitrief's provision of advisory services to the Company pursuant to the terms of the Agreement;

**WHEREAS**, the Company and Dimitrief desire to amend the Agreement pursuant to the terms of this Amendment, including to assign the rights and obligations of Dimitrief under the Agreement to the Consulting LLC to the extent provided for in this Amendment;

**WHEREAS**, the Company and Dimitrief continue to agree that, during the period when the Services are provided to the Company, Dimitrief will be provided with access to trade secrets and confidential information of the Company Group after Dimitrief's Retirement; and

**WHEREAS**, capitalized terms used in this Amendment that are not otherwise defined in this Amendment but are defined in the Agreement shall have the meanings for such terms as provided for under the Agreement.

**NOW, THEREFORE**, in consideration of the terms and conditions and mutual promises set forth or described in this Amendment, plus other good and valuable consideration, the receipt by the Parties and the sufficiency and adequacy of which are hereby acknowledged by such Parties, the Company, the Consulting LLC and Dimitrief hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>ASSIGNMENT</u>. The rights and obligations of Dimitrief under the Agreement are hereby assigned to the Consulting LLC subject to any limitations provided for in this Amendment; <u>provided</u>, <u>however</u>, that, in particular, Dimitrief shall remain subject to the obligations of the "Advisor" under the Agreement with respect to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.Being the sole provider of the Services to the Company (as opposed to the Consulting LLC or some other person or entity providing the Services to the Company) under the amended Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.Being solely responsible for, and having sole control over, the means, methods, techniques, sequences, and procedures used in providing the Services under the amended Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.Being solely responsible to pay all taxes that may be imposed on the Advisor as a result of the compensation under the amended Agreement, including the timely payment of estimated tax payments;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D.All restrictive covenant terms and conditions and adherence to Company policies requirements, including those set forth under Sections 5 and 6 of the Agreement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E.Delivery to the Company of all materials containing, reflecting, incorporating or based on Confidential Information pursuant to Section 8 of the amended Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>OTHER AGREEMENTS</u>. The Parties agree that, based on the expected service requirement under the amended Agreement, upon Dimitrief's Retirement, Dimitrief experienced a "separation from service" within the meaning of Treasury Regulation 1.409A-1(h), and that Dimitrief and the Consulting LLC are providing the Services pursuant to the amended Agreement as independent contractors to the Company (and, as of both the Agreement Effective Date and the Amendment Effective Date, are not employees of the Company or any of its affiliates). Further, the Parties agree that, Dimitrief has not been (since the Agreement Effective Date), and will not be, eligible to participate in any benefit plan offered by the Company Group to their employees. The Parties also agree that the Company Group has not made any representations or guarantees regarding the tax result for Dimitrief with respect to any income recognized by Dimitrief and/or the Consulting LLC in connection with the amended Agreement or any amounts payable under the amended Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>INCORPORATION OF AGREEMENT TERMS; CONTINUING EFFECT</u>. Except as expressly modified by this Amendment, the terms and provisions of the Agreement are hereby incorporated into this Amendment by reference and shall apply to this Amendment mutatis mutandis. Without limiting the foregoing, the provisions of the Agreement relating to amendment and waiver, governing law, entire agreement, notices, and counterparts (including the applicable sections thereof) shall govern this Amendment as if fully set forth herein.

*[signatures on following page(s)]*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

------

&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the Parties have executed this Amendment to be effective as of the Amendment Effective Date.

---

| |
|:---|
| **SOTERA HEALTH COMPANY** |
| /s/ Michael B. Petras, Jr. |
| Name: Michael B. Petras, Jr. |
| Title: Chief Executive Officer |
| **DIMITRIEF ADVISORY LLC** |
| /s/ Alexander Dimitrief |
| Name: Alexander Dimitrief |
| Title: Founder and Principal |
| **DIMITRIEF** |
| /s/ Alexander Dimitrief |
| Name: Alexander Dimitrief |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Michael B. Petras, Jr., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sotera Health Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:&nbsp;&nbsp;&nbsp;&nbsp;May 5, 2026

---

| |
|:---|
| /s/ Michael B. Petras, Jr. |
| Michael B. Petras, Jr. |
| Chairman and Chief Executive Officer |
| *(Principal Executive Officer)*  |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jonathan M. Lyons, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sotera Health Company;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:&nbsp;&nbsp;&nbsp;&nbsp;May 5, 2026

---

| |
|:---|
| /s/ Jonathan M. Lyons |
| Jonathan M. Lyons |
| Senior Vice President and Chief Financial Officer |
| *(Principal Financial Officer)*  |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Sotera Health Company (the "<u>Company</u>"), do hereby certify, to each such officer's knowledge, that the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Dated: May 5, 2026 | /s/ Michael B. Petras, Jr. |
|  | Michael B. Petras, Jr.<br>Title: Chairman and Chief Executive Officer<br>*(Principal Executive Officer)* |
| Dated: May 5, 2026 | /s/ Jonathan M. Lyons |
|  | Jonathan M. Lyons<br>Title: Senior Vice President and Chief Financial Officer<br>*(Principal Financial Officer)* |

---

The foregoing certifications are furnished and are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and are not deemed to be incorporated by reference into any filing of Sotera Health Company under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Sotera Health Company specifically incorporates them by reference.

<br>